Education/CredentialsResidency: Veteran's Administration Medical CenterDoctoral Degree: University of Tennessee (Pharmacy)Bachelor's Degree: Oral Roberts University (Pre-Pharmacy Curriculum) Contact Information Medical Sciences Building 6203 Office 513-558-5471 Email allowarr@ucmail.uc.edu Research InterestsKidney, Liver and Pancreas Solid Organ Transplantation Pharmacotherapy with the Goal of Individualizing Transplant Recipients' Immunosuppressive Regimens Based Upon Pharmacogenomic and Pharmacokinetic Immunosuprression Characterization, Novel Clinical Trial Design, Study Conduct Strategies with a Focus on Pharmacokinetic Studies Peer Reviewed Publications Sadaka B, Alloway RR, Shields AR, Schmidt N, Woodle ES 2012. Proteasome inhibition for antibody mediated allograft rejection Seminars in Hematology, , Schmidt N, Alloway RR, Walsh CC, Sadaka B, Wall A, Shields AR, Woodle ES 2012. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients Transplantation, , Sadaka B, Alloway RR, Woodle ES 2011. Clinical and investigational use of proteasome inhibitors for transplant rejection Expert Opinion on Investigational Drugs, 20 11, 1535-1542van Hooff JP, Alloway RR, Trunecka P, Mourad M 2011. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de nove kidney, liver, and heart studies Clin Transplant, 25 1, Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P 2011. Proteasome inhibitor therapy for antibody-mediated rejection Pediatric Transplantation, 15 6, 548-556Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Brown E, Woodle ES 2009. Proteasome inhibition reduces donor-specific antibody levels Transplant Proceedings, 41 1, 105-107Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Brown E, Woodle ES 2008. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection Transplantation, 86 , 1754-1761Rike AH, Mogilishetty G, Alloway RR, Succop P, Roy-Chaudhury P, Cardi M, Kaiser TE, Thomas M, Woodle ES 2008. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids Clinical Transplantation, 22 2, 229-235Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA 2008. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgey in end-stage renal disease and transplant patients: a pilot study Clin Transplant, 22 3, 281-291Weimert NA, Alloway RR 2008. Monoclonal antibodies in solid organ transplantation Pharmaceutical Biotechnology: Fundamentals and Applications, , 365-375Whitaker I, Guggan EM, Alloway RR, Brown C, McGuire S, Woodle ES, Banis JC, Maldonado C, Barker JH 2008. Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons Journal of Plastic, Reconstructive and Aesthetic Surgery , 61 5, 481-492Vasilic D, Alloway RR, Barker JH, Furr A, Askcroft R, Banis JC Jr, Kon M, Woodle ES 2007. Risk assessment of immunosuppressive therapy in facial transplantation Plast Recontstr Surg, 120 3, 657-668Vasilic D, Alloway RR, Furr A, Ashcroft R, Kon M, Banis JC, Barker JH, Woodle ES 2007. Risk assessment of immunosuppressive therapy in facial transplantation Plastic and Reconstructive Surgery , 120 3, 657-668Weimert NA, Alloway RR 2007. Renal transplantation in high risk patients Drugs, 67 11, 1603-1627Weimert NA, DeRotte M, Alloway RR, Vinks AA, Woodle ES 2007. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications Ther Drug Monitor, 29 , 141Alexander JW, Metze TJ, Goodman HR, Cardi M, Austin J, GOel S, Safdar S, Huang S, Munda R, Fidler J, Buell JF, Hanaway MJ, Susskind B, Greenburg N, Trofe J, Alloway RR, Woodle ES 2006. Simultaneous corticosteroid and calcineurin inhibitor minimization European Society for Organ Transplantation, 19 , 295-302Alexander JW, Goodman HR, Alloway RR, Woodle ES 2005. Can immunonutrients reduce rejection rates in African Americans? Experimental and Clinical Transplantation, 2 , 349-350Alloway RR, Hanaway MF, Trofe J, Boardman R, Rogers CC, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2005. A prospective pilot study of early corticosteroid elimination under modern immunsuppression in patients at high immunologic risk: The Cincinnati experience Graft, 7 1, 10-11Alloway RR, Hanaway MF, Trofe J, Boardman R,Rogers CC, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2005. A prospective pilot study of early corticosteroid cessation in high immunologic risk patients: The Cincinnati Experience Transplant Proc, 37 , 802-803Boardman R, Trofe J, Alloway RR, Rogers CC, Roy-Chaudhury P, Cardi M, Buell JF, Hanaway M, Thomas MJ, Alexander JW, Munda R, Woodle ES 2005. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis Transplantation Proceedings, 37 , 817-818Boardman RE, Alexander JW, Alloway RR, Buell JF, Clippard M, Gupta M, Hanaway M, Merchen T, Metze T, Munda R, Peddi VR, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES 2005. African American renal transplant recipients benefit from early corticosteroid cessation under modern immunosuppression American Journal of Transplantation, 5 , 356-365Boardman RE, Alexander JW, Alloway RR, Buell JF, Clippard M, Gupta M, Hanaway M, Merchen T, Metze T, Munda R, Peddi VR, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES 2005. African American renal transplant recipients benefit from early corticosteroid cessation under modern immunosuppression Transplantation Proceedings, 37 , 814-816Buell JF, Beebe TM, Gross TG, Trofe J, Hanaway MJ, Alloway RR, First MR, Woodle ES 2005. United network for organ sharing publication on scientific registry of Transplant Recipients Central Nervous System Donor Cancer Transmission Data Transplantation, 79 5, 623Buell JF, Gross T, Alloway RR, Trofe J, Woodle ES 2005. Central Nervous System Tumors in Donors: Misdiagnosis carries a high morbidity and mortality Transplant Proc, 37 , 583-584Buell JF, Gross TG, Hanaway MH, Trofe J, Muthiak C, First MR, Alloway RR, Woodle ES 2005. Chemotherapy for PTLD: The Israel Penn International Transplant Tumor Registry Experience Transplantation Proceedings, 37 , 956-957Buell JF, Hanaway MJ, Thomas MJ, Alloway RR, Woodle ES 2005. Skin cancer following transplantation: The Israel Penn International Transplant Tumor Registry Experience Transplantation Proceedings, 37 , 962-963Buell JF, Hanaway MJ, Thomas MJ, Munda R, Alloway RR, First MR, Woodle ES 2005. Donor kidneys with small renal cell cancers: can they be transplanted? Transplant Proceedings, 37 , 581-582Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, WOodle ES 2005. De novo colorectal cancer: Five-year survival is markedly lower in transplant recipients compared to the general population Transplant Proceedings, 37 , 960-961Hanaway MJ, Roy-Chaudhury P, Buell JF, Thomas MJ, Munda R, Alloway RR, Ellison V, Rudich SM, Fisher L, Woodle ES 2005. Pilot study of early corticosteroid elimination after pancreas transplantation Transplant Proceedings, 37 , 1287-1288Rogers C, Alloway RR, Boardman R, Trofe J, Hanaway M, Alexander J, Roy-Chaudhury P, Buell J, Thomas M, Cardi M, Susskind B, Woodle ES 2005. Global Cardiovascular Risk under Early Steroid Cessation Decreases Progressively in the First Year Post Transplant Graft, 7 1, 38-39Rogers CC, Alloway RR, Boardman R, Trofe J, Hanaway MJ, Alexander JW, Roy-Chaudhury P, Buell JF, Thomas MJ, Susskind D, Woodle ES 2005. Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation Transplantation Proceedings, 37 , 812-813Rogers CC, Alloway RR, Hanaway M, Buell JF, Roy-Chaudhury P, Succop P, Woodle ES 2005. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression Transplant Proc, 37 , 800-801Rogers CC, Hanaway M, Alloway RR, Alexander JW, Boardman RE, Trofe J, Gupta M, Merchen T, Buell JF, Cardi M, Roy-Chaudhury P, Succop P, Woodle ES 2005. Corticosteroid avoidance ameliorates lymphocele formation and would healing complications associated with sirolimus therapy Transplant Proc, 37 , 795-797Rogers J, Stratta RJ, Lo A, Alloway RR 2005. Inferior late functional and metabolic outcomes in African American simultaneous kidney-pancreas recipients Transplant Proc, 37 8, 3552-3554Trofe J, Buell JH, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES 2005. The Israel Penn International Transplant Tumor Registry experience with 402 renal transplant recipients with post transplant lymphoproliferaitve disorder: Multivariate analysis of risk factors that influence survivial American Journal of Transplantation, 5 4 (pt 1), 775-780Woodle ES, Alloway RR, Hanaway MJ, Buell JF, Thomas MJ, Roy-Chaudhury P, Trofe J 2005. Early corticosteroid withdrawal under modern immunosuppression in renal transplantation Transplantation Proceedings, 37 , 798-799Woodle ES, Alloway RR, Succop P. Thomas M, Buell J, Tevar A, Munda R, Roy-Chuadhury P, Cardi M, Trofe J 2005. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression American Journal of Transplantation, 5 11, 2740-2744Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas MJ, Buell JF, ALexander JW, Roy-Chaudhury P, Succop P, Cardi M, Boardman R, Rogers CC 2005. Histocompatability testing predicts acute rejection risk in early corticosteroid withdrawal regimens Transplantation Proceedings, 37 , 809-811Alloway RR, Trofe J, Boardman R, Rogers CC, Hanaway MJ, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2004. A prospective pilot study of early corticosteroid elimination under modern immunosuppression on patients at high immunologic risk: The Cincinnati experience Graft, 7 1, 10-11Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Beebe T, Woodle ES, Buell JF 2004. Experience with 274 cardiac transplant recipients post-transplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry Transplantation, 11 , 1676-1682Buell JF, Beebe TM, Gross TG, Trofe J, Hanaway MJ, Alloway RR, First MR, Woodle ES 2004. Donor transmitted malignancies Ann Transplant, 9 1, 53-56Papaconstantinou HT, Sklow B, Hanaway MJ, Gross TG, Beebe TM, Trofe J, Alloway RR, Woodle ES, Buell JF 2004. Characteristics and survival patters of solid organ transplant patients developing de novo colon and rectal cancer Dis Colon Rectum, 47 11, 1898-1903Rogers J, Stratta RJ, Alloway RR, Lo A, Hodge EE and PIVOT Investigators 2004. African-American Ethnicity is no longer a risk factor for early adverse outcome in simultaneous kidney-pancreas transplant with contemporary immunosuppression Transplant Proceedings, 36 4, 1055-1057Stratta RJ, Alloway RR, Lo A, Hodge E 2004. Does surgical techniqu influence outcomes after simultaneous kidney-pancreas transplantation? Transplant Proceedings, 36 4, 1076-1077Stratta RJ, Alloway RR, Lo A, Hodge E and PIVOT Investigators 2004. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative-dosing regimen of Daclizumab Transplant Proc, 36 4, 1080-1081Trofe J, Beebe TM, Buell JF, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES 2004. Post-Transplant Malignancies Progress in Transplantation, 14 3, 193-200Trofe J, Buell JF, Woodle ES, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG 2004. Recurrence risk following organ transplantation in patients with a history of Hodgkin's disease or non-Hodgkin's lymphoma Transplantation, 78 7, 972-977Alloway RR, Isaacs R, Lake K, Hoyer P, First MR, Helderman H, Bunnapradist S, Leichtman A, Bennett W, Tejani A, Takemoto S 2003. Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants American Journal of Transplantation, 10 , 1211-1215Buell JF, Trofe J, Sethuraman G, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2003. Donors with central nervous system malignancies: are they truly safe? Transplantation, 76 2, 340-343Stratta RJ, Alloway RR, Hodge E, Lo A, PIVOT Investigators 2003. Two Dose Daclizumab Regimen Provides Superior Outcomes in Simultaneous Kidney/Pancreas Transplant Recipients: Primary Endpoint Analysis of a Multi-Center Randomized Study Transplantation, 75 8, 1260-1266Trofe J, Gaber LW, Stratta RJ, Shokouh-Amiri HS, Grewal HP, Vera SR, Reed L, Alloway RR, Lo A, Gaber AO 2003. Polyomavirus in kidney and kidney-pancreas transplant recipients Transplant Infectious Disease , 5 1, 21-28Trofe J, Gordon J, Roy-Chaudhury P, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalili K, Woodle ES 2003. Polyomavirus nephropathy in kidney and kidney-pancreas transplantation Journal of Neurovirology, 9 Suppl 2, 48Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES 2003. Basic and clinical research in polyomavirus nephropathy Exp Clin Transplant, 2 1, 162-173Trofe J, Roy-Chaudhury P, Gordon J, Mutema G, Cavallo T, Cardi M, Austin J, Goel S, Rogers C, Boardman R, Clippard M, Alloway RR, Alexander JW, Metze T, Goodman H, Hanaway MH, Munda R, Buell JF, Peddi VR, Safdar S, HUang S, Fidler J, Khalili K, Woodle ES 2003. Early Steroid Cessation/Avoidance Regimens are Associated with a Lower Incidence of Polyoma Virus Nephropathy Compared to Steroid Based Immunosuppression in Kidney Transplant Recipients Transplantation Review, 17 4, S52-S53Witherow BA, Roth GS, Carrozza MA, Freyberg RG, Kopke JE, Alloway RR, Buell JF, First MR, Gross TG, Hanaway MJ, Troge J, Woodle ES, Beebe TM 2003. The Israel Penn International Transplant Tumor Registry Proc AMIA Sympo, , 1053Woodle ES, Roy-Chaudhury P, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalil K, Gordon J, Trofe J 2003. Pathology of polyomavirus nephropathy in renal transplant recipients Journal of Neurovirology, 9 Suppl 2, 16Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker M, Alloway RR, Meibohm B 2003. The effect of CYP3A5 and MDR1 Polymorphis Expression on Cyclosporine Oral Disposition in Renal Transplant Patients The Journal of Clinical Pharmacology, 43 6, Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2002. Immunosuppression and Merkel Cell Cancer Transplant Proc, 34 5, 1780-1781Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2002. De novo breast cancer in renal transplant recipients Transplant Proc, 34 5, 1778-1789Honaker MR, Stratta RJ, Lo A, Egidi MF, Amiri S, Grewal HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO 2002. Impact of HCV status in pancreas transplantation: a case controlled study Clin Transplant, 16 , 1-9Honaker MR, Stratta RJ, Lo A, Egidi MF, Amiri S, Grewal HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO 2002. Impact of hepatitis C virus status and pancreas transplantation: A case controlled study Clin Transplant, 16 4, 243-251Lo A, Alloway RR 2002. Strategies to Reduce Toxicities and Improve Outcomes in Renal Transplant Recipients Pharmacotherapy, 22 3, 316-328Lo A, Stratta RJ, Trofe J, Norwood J, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Gaber AO 2002. Rhodococcus Equi Pulmonary Infection in a Pancreas Alone Transplant Recipient: Consequence of Intense Immunosuppression Transplant Infectious Disease , 4 , 46-51Stratta RJ, Alloway RR, Hodge E, Lo A for the PIVOT study group 2002. A multicenter, open-label, comparative trial of two Daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis Clin Transplant, 16 1, 60-68Stratta RJ, Alloway RR, Lo A, Hodge E 2002. A multicenter trial of two dosing strategies versis no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis Transplant Proc, 34 5, 1903-1905Trofe J, Cavallo TC, First MR, Weiskittel P, Peddi VR, Roy-Chaudhury P, Alloway RR, Safdhar S, Buell JF, Hanaway MJ, Woodle ES 2002. Polyomavirus in kidney and kidney pancreas transplantation: a defined protocol for immunosuppression reduction and histologc monitoring Transplant Proc, 34 5, 1788-1789Trofe J, Stratta RJ, Egidi MF, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Honaker M, hardinger K, Alloway RR, Gaber AO 2002. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single center experience Clin Transplant, 7 Suppl 16, 34-44Buell JF, Trofe J, Hanaway MJ, Rilo H, Alloway RR, Beebe T, First MR, Woodle ES 2001. Transmisison of Donor Cancer into Cardio-Thoracic Transplant Recipients Surgery, 130 , 660-668Buell JF, Trofe J, Hanaway MJ, Rilo H, Alloway RR, Beebe T, First MR, Woodle ES 2001. Transmission of Donor Cancer into Cardio-Thoracic Transplant Recipients Surgery, 130 , 660Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera SR, Grewal HP, Alloway RR, Gaber AO 2001. Post Transplant Lymphoproliferative Disorders: A Single Center Experience Transplant Proceedings, 33 1-2, 1838-1839Hardinger KL, Stratta RJ, Egidi MF, Amiri MH, Grewal HP, Honaker MR, Vera SR, Alloway RR, Gaber LW, Gaber AO 2001. Renal Allograft Outcomes in African-American versus Caucasian Transplant Recipients in the Tacrolimus Era Surgery, 130 , 738-748Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO 2001. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil, and steroids in simultenous kidney-pancreas transplantation Transpl Int, 14 6, 396-404Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO 2001. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation Transplant Proc, 33 1-2, 1701-1703Lo A, Stratta RJ, Egidi MF, Kizilizik TA, Amiri MH, Grewal HP, Alloway RR, Trofe J, Gaber AO 2001. Ganciclovir Prophylaxis for CMV Infection in Simultaneous Kidney-Pancreas Transplant Recipients Receiving Tacrolimus, Mycophenolate Mofetil, and Prednisone Transplant Proc, 33 1-2, 1768-1769Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO 2001. Outcome of simultaneous kidney-pancreas transplantation in African-American recipients: a case control study Transplant Proc, 33 1-2, 1675-1677Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO 2001. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus mycophenolate mofetil, and prednisone with ganciclovir prophylaxis Transplant Infectious Disease , 3 , 8-15Lo A, Stratta RJ, Hathaway DK, Egidi MF, Amiri MH, Grewal HP, Winsett RP, Trofe J, Alloway RR, Gaber AO 2001. Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric vs. systemic-bladder drainage American Journal of Kidney Diseases, 38 , 132-143Lo A, Stratta RJ, Hathaway DK, Egidi MF, Amiri MH, Grewal HP, Winsett RP, Trofe J, Alloway RR, Gaber AO 2001. Long term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage Transplant Proc, 33 1-2, 1684-1686Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RH, Nezakatgoo N, Trofe J, Alloway RR, Gaber AO 2001. The importance of early prevention of renal dysfunction in liver transplant recipients Transplant Proc, 33 1-2, 1399-4000Stratta RJ, Alloway RR, Lo A, Hodge E 2001. A multicenter trial of two Daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis Transplant Proc, 33 1-2, 1692-1693Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Alloway RR, Hathaway DK, Gaber LW 2001. Nine-year experience with 126 pancreas transplants with portal-enteric drainage Transplant Proc, 33 1-2, 1687-1688Trofe J, Reddy KS, Stratta RJ, Flax SD, Somerville KT, Alloway RR, Egidi MF, Shokouh-Amiri MH, Gaber AO 2001. Human granulocytic ehrlichiosis in pancreas transplant recipients Transplant Infectious Disease , 3 1, 34-39Tujeta S, Alloway RR, Johnson JA, Gaber AO 2001. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients Transplantation, 71 , 1303-1307Winset RP, Stratta RJ, Alloway RR, Wicks MN, Hathaway DK 2001. Immunusuppressant side effect profile does not differ between organ transplant tupes Clin Transplant, 15 Suppl 6, 46-50Hurst GC, Alloway RR, Somerville KT, Gaber AO, Stratta RJ 2000. Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension Clin Transplant, 14 , 42-47Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO 2000. Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: A cas control study Clin Transplantation, 14 , 572-579Reddy KS, Stratta RJ, Shokouh-Amiri MH, Alloway RR, Somerville T, Egidi MF, Gaber AO 2000. Simultaneous kidney-pancreas transplantation without antilymphocyte induction Ann Surg, 69 , 49-54Alloway RR 1999. Generic immunosuppressant use in solid organ transplantation Transplant Proc, 31 , 2S-5SAlloway RR, Somerville TK 1999. Transplantation: Solid Organ. Basic Bibliographies Hospital Pharmacy, 34 , 379Alloway RR, Somerville TK 1999. Transplantation Immunusuppression. Basic Bibliographies. Hospital Pharmacy, 34, 380Gaston R, Alloway RR, Gaber AO, Schroeder TJ, Irish WD, Canafax DM, First MR 1999. Pharmacokinetics and safety evaluation of SangCya vs Neoral or Sandimmune in stable retransplant recipients Transplant Proc, 31 , 326-327Meier-Kriesch HU, Alloway RR, Gaber AO, Canafax D, Kaplan B 1999. A limited sampling strategy (LSS) for the estimation of 12-hour SangCya and Neoral AUCs in renal transplant recipients J Clin Pharmacol, 39 , 166-167Reddy KS, Stratta RJ, Shokouh-Amiri MH, Alloway RR, Egidi MF, Gaber AO 1999. Surgical complications after pancreas transplantation with portal-enteric drainage J Am Coll Surg, 189 , 305-313Stratta RJ, Gaber AO, Shokouh-Amiri MH, Reddy KS, Alloway RR, Egidi MF, Grewal HP, Gaber LW, Hathaway D 1999. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction Ann Surg, 229 , 709-712Stratta RJ< Gaber AO, Shoukouh-Amiri MH, Reddy S, Alloway RR, Egidi MF, Grewal HP, Gaber LW, Hathaway DK 1999. Evolution in Pancreas Transplantation Techniques: Simultaneous Kidney-Pancreas Transplantation Using Portal-Enteric Drainage Without Antilymphocyte Induction Ann Surg, 229 , 701-712Alloway RR, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO 1998. Bioequivalence comparison of Snadimmune and Neoral versus Sang-35 cyclosporine in kidney transplant recipients J Am Soc Nephrol, 8 , 672AFirst MR, Alloway RR, Schroeder TJ 1998. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral Clin Transplantation, 12 , 518-524Hurst G, Alloway RR, Hathaway D, Somerville T, Hughes T, Gaber AO 1998. Stabilization of bone mass after renal transplant with preemptive care Transplant Proc, 30 , 1327-1328Somerville T, Hurst G, Alloway RR, Gaber AO, Shokouh-Amiri MH, Stratta R 1998. Superior efficacy of oral gancyclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients Transplant Proc, 30 , 1546-1548Stratta RJ, Alloway RR 1998. Pancreas transplantation for diabetes mellitus: A guide to recipient selection and optimum immunosuppression Biodrugs, 10 5, 347-357Winsett RP and the Posttransplant Quality of Life Intervention Study Group 1998. Posttransplant quality of life: a decade of descriptive studies leading to practice interventions J Transplant Coordination, 8 , 236-240Gaber LW, Moore LW, Reed L, Russell W, Alloway R, Hathaway D, Shokough-Amiri MH, Gaber AO 1997. Renal histology with varying FK 506 blood levels Transplant Proc, 29 , 186Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO 1996. Conversion from Cyclosporine to tacrolimus in kidney, kidney/pancreas and pancreas alone transplant recipients: the Memphis Experience Transplant Proc, 28 , 995-997Elmer D, Nymann T, Hathaway D, Alloway RR, Gaber AO 1996. Use of FK-506 immunosuppression in pancreas transplant J Transplant Coordination, 6 , 122-127Gaberr LW, Moorle LW, Alloway RR, Flax S, Schroeder T, Amiri H, Gaber AO 1996. Correlation between BANFF scores of acute renal rejection scores and reversal of rejection Kidney Int, 49 , 481-497Moore LW, Alloway RR, Smith SO, Acchiardio SR, Gaber AO 1996. Clinical obsevations of metabolic changes occurring in renal transplant recipients receiving ketoconazole Transplantation, 61 , 537-541Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO 1996. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation Clin Transplantation, 10 , 633-667Self T, Alloway R 1996. Treatment of Rhinitis J Am Acad Nurse Pract, 8 , 135-144Gaber LW, Moore LW, Alloway RR, Flax S, Gaber AO 1995. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection Transplant Proc, 27 , 1019Gaber LW, Moore LW, Alloway RR, Shokouh-Amiri MH, Vera SR, Gaber AO 1995. Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts Transplantation, 60 , 334-339Alloway RR, Kotb M, Hathaway D, Ohman M, Gaber AO 1994. Pharmacokinetic Profile of OKT3 in Renal Transplant Recipients Receiving Standard and Low Dose OKT3 for Induction Immunosuppression Transplantation, 58 , 249-253Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1993. Results of Prospective, Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy Transplant Proc, 25 1, 550-552Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1993. Results of a Prospective, Randomized, Double-Blind Study Comparing Standard versus Low Dose OKT3 Induction Therapy American Journal of Kidney Diseases, 22 36-43, Self T, Heilker G, Alloway RR, Kelso T, Abou-Shala N 1993. Reassessing the Therapeutic Range for Theophyilline on Laboratory Report Forms: The Importance of 5-15 mcg/ml Pharmacotherapy, 13 6, 590-594Alloway RR, Kotb M, Gaber L, Boskey F, Gaber AO 1992. Standard versus Low Dose OKT3 Induction of Cadaveric Renal Transplants: Compairson of Outcome Data versus OKT3 Dose and Serum LEvels Clin Transplantation, 46 , 468-472Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1992. Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients Scientia, 1 6, Kelso TM, Alloway RR, Self TH 1992. Asthma Patient Education Journal of Pharmacy Practice, 5 , 186-196Busque S, Cantarovich M, Mulgonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators 12-2011. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation Am J Transplant, 11 12, 2675-2684Trofe-Clark J, Gabardi S, McDevitt-Potter L, Alloway RR 12-17-2011. Immunosuppression. Generic Drugs and the FDA Am J Transplant, , Bruce DS, Sollinger HW, Humar A, Sutherland DER, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ 11-27-2001. Multicenter Survey of Daclizumab Induction in Simultaneous Kidney-Pancreas Transplant Recipients Transplantation, 72 10, 1637-1643Buell JF, Alloway RR, Woodle ES 10-2006. How can donors with a previous malignancy be evaluated? J Hepatol, 45 4, 503-507Rogers J, Stratta RJ, Lo A, Alloway RR 10-2005. Impact of metabolic syndrome on long-term outcomes in simultaneous kidney-pancreas transplantation Transplant Proc, 37 8, 3549-3551Stratta RJ, Alloway RR, Lo A, Hodge E 10-2005. Risk factors and outcomes analyses of a prospective, randomized, multicenter trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients Transplant Proc, 37 8, 3527-3530Winsett RP, Arheart K, Stratta RJ, Alloway RR, Wicks MN, Gaber AO, Hathaway DK 09-2004. Evaluation of an immunosuppressant side effect instrument Prog Transplant, 14 3, 210-216Honaker MR, Amiri S, Vera SR, Alloway RR, Grewal HP, Hardinger KL, Kizilisik TA, Bagous T, Trofe J, Stratta RJ, Egidi MF, Gaber AO 09-2002. Evolving experience of HBV prophylaxis in liver transplantation Transplant Infectious Disease , 4 3, 137-143Self T, Alloway R 09-1993. Nonsedating Antihistamines Pharmacy Newsletter, , Alloway RR, Dupuis R, Gabardi S, Kaiser TE, Taber DJ, Tichy EM, Weimert-Pilch NA; American Society of Transplantation Transplant Pharmacy Community of Practice and the American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network 08-2011. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team Am J Transplant, 11 8, 1576-1583Woodle ES, Alloway RR, Girnita A 08-2011. Proteasome inhibitor treatment of antibody-mediated allograft rejection Curr Opin Organ Transplant, 16 4, 434-438Buell JF, Thomas GG, Thomas MJ, Neff G, Muthiah C, Alloway RR, Woodle ES 08-2006. Malignancy in pediatric transplant recipients Seminars in Pediatric Surgery, 15 3, 179-187Gaber AO, Mulgaonkar S, Kahan BD, Woodle ES, Alloway RR, Bajjoka I, Jensik S, Klintmalm GB, Patton PR, Wiseman A, Lipshutz G, Kupiec-Weglinski J, Gaber LW, Katz E, Irish W, Squiers EC, Hemmerich S 07-2011. YSPSL (rPSGL-Ig) for improvement of early renal allograft function; a double-blind, placebo-controlled, multi-center Phase IIa study Clin Transplant, 25 4, 523-533Rogers CC, Alloway RR, Buell JF, Boardman R, Aelxander JW, Cardi M, Roy-Chaudhury P, First MR, Succop P, Munda R, Woodle ES 07-15-2005. Body weight alterations under early coticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression Transplantation, 80 1, 26-33Alloway RR, Steinburg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsh J, Martas A, Zaltzman J, Wisemandel K, Fitzsimmons W, First MR 06-27-2007. Two years postconversion from a prograf-based regimen to a once daily tacrolimus extended-release formulation in stable kidney transplant recipients Transplantation, 83 12, 1648-1651Florman S, Alloway RR, Kalayoglu M, Punch J, Bak T, Melancon J, Klintmalm G, Busque S, Charlton M, Lake J, Dhadda S, Wisemandle K, Wirth M, Fitzsimmons W, Holman J, First MR 06-27-2007. Once daily tacrolimus extended release formulation: experience at 2 years post conversion from a Prograf-based in stable liver transplant recipients Transplantation, 83 12, 1639-1642Reddy KS, Stratta RJ, Alloway RR, Lo A, Hodge EE; PIVOT Study Group 05-2004. The impact of delayed graft function of the kidney on the pancreas allograft in simultaneous kidney-pancreas transplantation Transplant Proc, 36 4, 1078-1079Stratta RJ, Alloway RR, Hodge E, Lo A, PIVOT Investigators 05-2004. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients Transplant Proc, 36 4, 1082-1083First MR, Alloway RR, Fisher RA, Pan SH, Lopez R, Renlund D, Schnitzler M, Gaber AO 05-2000. Generic drug substitution in transplantation: examples from the epic of Cyclosporine development Dialysis and Transplantation, 29 5, 260-267Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES 04-2004. Polyomavirus in Solid Organ Transplantation Progress in Transplantation, 14 2, 130-140Vasilic D, rteynolds CC, Cunningham M, Furr A, Storey B, Banis JC, Wiggins O, Maldonado C, Alloway RR, Kon M, Barker JH 03-2008. Plastic surgeon's risk acceptance in facial transplantation Plast Recontstr Surg, 121 3, 41e-48eFlorman S, Alloway RR, Kalayoglu M, Lake K, Bak T, Klein A, Klintmalm G, Busque S, Brandenhagen D, Lake J, Widemandle K, Fitzsimmons W, First MR 03-2005. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen Transplant Proc, 37 2, 1211-1213Lo A, Stratta RJ, Alloway RR, Hodge EE; PIVOT Study Group 03-2005. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation Transplant Proc, 37 2, 1289-1290Walker JK, Alloway RR, Roy-Chaudhury P, Mogilishetty G, Cardi M, Weimert NA, Rike AH, First MR, Woodle ES 02-15-2006. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in HLA identical live donor renal transplantation Transplantation, 87 3, 408-414Aull MJ, Buell JF, Peddi VR, Trode J, Beebe TM, Hanaway MH, Roy-Chaudhury P, Alloway RR, First MR, Woodle ES; Israel Penn International Transplant Tumor Registry 01-2002. MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report form the Israel Penn International Transplant Tumor Registry with a review of published literature Transplantation, 75 2, 225-228Alloway RR 01-1994. Spotlight of Heparin Dosing. Drug Information Update, Allied Pharmacy Management Inc, , Abstract Publications Merchen T, Gupta M, First MR, Trofe J, Gross TG, Bebe TM, Alloway RR, Muthiah C, Hanaway MG, Buells JF, Woodle ES 2003. PTLD following lung transplantation American Transplant Congress, Washington, D.C., , Aull MJ, Trofe J, First MR, Hanaway M, Beebe TM, Alloway RR, Woodle ES, Buell JF 2001. Maltoma: infectious etiology of malignancy in transplant patients International Transplant Nurses Society, , Beebe TM, Buell JF, Alloway RR, Hanaway MJ, First MR, Woodle ES 2001. Donor transmission of a renal cell carcinoma from a living related donor to a kidney recipient International Transplant Nurses Society, , Moore LW, Alloway RR, Smith SO, Acchiardio SR, Gaber AO 1995. Ketaconazole enhances loss of bone in renal transplant recipients American Society of Transplantation Physicians Annual Meeting, , Alloway RR, Kotb M, Hathaway D, Schroeder T, Gaber AO 1994. Demographic and clinical factors effecting TCR expression during and following OKT3 treatment The American Society of Nephrology, , Gaber L, Moore L, Alloway RR, Flax S, Gaber AO 1994. Correlation Between BANFF Classification, Acute Renal Rejection Scores and Reversal of Rejection American Society of Transplantation Physicians, , Gaber L, Vera S, Hathaway D, Salem A, Alloway RR, Gaber AO 1993. Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function American Society of Nephrologists/National Kidney Foundation, , Gaber L, Vera S, Hathaway D, Salem A, Alloway RR, Gaber AO 1992. Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function National Kidney Foundation, , Gaber AO, Kotb M, Winsett RP, Gaber LW, Vera SR, Phillips D, Boskey FD, Alloway RR 1991. Standard Versus Low Dose OKT3 Induction: Comparison of Immune Monitoring Data and Results. Proceedings of the American Society of Transplant Physicians, , 1Winsett RP, Hathaway DK, Alloway RR, Gaber AO 1991. Effective and Safe Use of Ketoconazole as Adjunctive Immunosuppressive Therapy. North American Transplant Coordinators Organization, , Gaber AO, Shoukouh-Amiri MH, Stratta RJ, Reddy KS, Alloway RR, Britt LG 12-1998. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction Southern Surgical Association Annual Meeting, , Sollinger HW, Bruce DS, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, Alloway RR, Stratta RJ 08-1999. Multicenter analysis of Daclizumab induction in simultaneous kidney pancreas transplant recipients 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS 08-1999. A single center experience with 108 cases of pancreas transplantation with portal-enteric drainage 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS, Gaber AO 08-1999. Graft failure after solitary pancreas transplantation 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS, Gaber AO 08-1999. Patterns of graft loss after simultaneous kidney-pancreas transplantation according to technique and immunosuppressive era 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO 08-1995. Conversion from cyclosporine to FK-506 in kidney, kidney/pancreas and pancreas alone transplant recipients. A single center experience Minneapolis Transplant Congress: New Immunosuppressive Drugs, Minneapolis, MN, , Elmer D, Nymann T, Hathaway D, Alloway RR, Gaber AO 08-1995. Use of FK0506-based immunosuppression in pancreas transplantation National Association of Transplant Coordinators Organization Annual Meeting, Boston, MA, , Regan J, Alloway RR, Rossi S, Campbell K, Buelow R, Lankford M, Gaber AO 07-1998. Clinical monitoring of cyclosporine: Capillary whole blood collected with the cyclostat collection device XVII World Congress of the International Transplant Society, Montreal, Canada, , Gaber LW, Lo A, Egidi MF, Stratta RJ, Amiri MH, Grewal HP, Kizilisik T, Alloway RR, Gaber AO 05-2000. Relationship of histological and clinical features of first acute rejection on recurrent rejection and pancreas failure First Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, , Stratta RJ, Allwoay RR, Hodge E 05-2000. An open-label, comparative trial of two Daclizumab dosing strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients: Interim analysis First Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, , Egidi MF, Trofe J, Reed L, Gaber LW, Alloway RR, Shoukouh-Amiri MH, Stratta RJ, Gaber AO 05-1999. Risk factors for polyoma virus: A comparative analysis in kidney-pancreas and kidney transplants 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Sollinger HW, Bruce D, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, Alloway RR, Stratta RJ 05-1999. Multicenter retrospective analysis of simultaneous kidney pancreas transplant recipients receiving Daclizumab induction 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Trofe J, Alloway RR, Godkin J, Kano J, Stratta RJ, Gaber AO 05-1999. Thymoglobulin for the prophylaxis or treatment of rejection in pancreas allograft recipients: Results of the US compassionate use experience 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Alloway RR, Canafax D, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO 05-1998. Bioequivalence of Snag-25 and Neoral for cyclosporine metabolites in stable renal transplant patients American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Hurst GC, Alloway RR, Somerville KT, Gaber AO, Stratta RJ 05-1998. Preliminary experience with midodrine in kidney/pancreas transplant patients experiencing orthostatic hypotension American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Hurst GC, Somerville KT, Alloway RR, Hathaway D, Moore LW, Gaber AO 05-1998. Continued loss of bone density one-year post kidney transplant despite preemptive therapy American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Alloway RR, Johnson JA, Chaballa M, Russell W, Reed L, Hathaway DK, Amiri H, Vera SR, Gaber AO 05-1997. Effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients American Society of Transplantation Surgeons Annual Meeting, Chicago, IL, , Alloway RR, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO 05-1997. An open-labeled single center bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Chaballa M, Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 05-1997. Five-year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Schroeder TJ, First R, Alloway RR, Gaber AO, Levy R, Berger-Moran H, Floch R, Pouletty P 05-1997. A program to develop cyclosporine formulation that is bioequivalent to Neoral American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Gaber LW, Moore LW, Russell W, Alloway RR, Gaber AO 05-1996. Donor glomerulosclerosis impacts both short- and long-term renal allograft function American Society of Transplantation Physicians Annual Meeting, Dallas, TX, , Gaber LW, Moore L, Alloway RR, Flax S, Schroeder T, Amiri H, Gaber AO 05-1995. Correlation between BANFF scores of acute renal rejection scores and reversal of rejection American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Gaber LW, Moore LW, Alloway RR, Shokouh-Amirir MH, Vera SR, Gaber AO 05-1995. Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Rageuh I, Kotb M, Fraga D, Schroeder T, Chan F, Russell WC, Alloway RR, Gaber AO 05-1995. A comparison of methodologies used for measurement of circulating OKT3 levels American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Abell TL, Horn J, Adl D, Self T, Soberman J, Alloway RR, Thompson L 04-1999. Correlation of cisapride levels with EKG changes: A pilot clinical observation Digestive Diseases Week Meeting of the American Gastroenterology Association, , Mendez R, Noriega A, Lowance D, Alloway RR, Lee I, Coggon G 03-1997. Valaciclovir reduces the incidence of CMV disease CMV-seropositive cadaveric renal allograft recipients Sixth Internatioanl Cytomegalovirus Workshop, Minneapolis, MN, , Nymann T, Vera SR, Amiri MH, Riely C, Alloway RR, Gaber AO 01-1996. Prevention of Hepatitis B recurrence with indefinite immunoprophylaxis after liver transplantation South Eastern Organ Procurement Foundation Tri-Annual Meeting, Orlando, FL, ,
Research InterestsKidney, Liver and Pancreas Solid Organ Transplantation Pharmacotherapy with the Goal of Individualizing Transplant Recipients' Immunosuppressive Regimens Based Upon Pharmacogenomic and Pharmacokinetic Immunosuprression Characterization, Novel Clinical Trial Design, Study Conduct Strategies with a Focus on Pharmacokinetic Studies
Peer Reviewed Publications Sadaka B, Alloway RR, Shields AR, Schmidt N, Woodle ES 2012. Proteasome inhibition for antibody mediated allograft rejection Seminars in Hematology, , Schmidt N, Alloway RR, Walsh CC, Sadaka B, Wall A, Shields AR, Woodle ES 2012. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients Transplantation, , Sadaka B, Alloway RR, Woodle ES 2011. Clinical and investigational use of proteasome inhibitors for transplant rejection Expert Opinion on Investigational Drugs, 20 11, 1535-1542van Hooff JP, Alloway RR, Trunecka P, Mourad M 2011. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de nove kidney, liver, and heart studies Clin Transplant, 25 1, Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P 2011. Proteasome inhibitor therapy for antibody-mediated rejection Pediatric Transplantation, 15 6, 548-556Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Brown E, Woodle ES 2009. Proteasome inhibition reduces donor-specific antibody levels Transplant Proceedings, 41 1, 105-107Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Brown E, Woodle ES 2008. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection Transplantation, 86 , 1754-1761Rike AH, Mogilishetty G, Alloway RR, Succop P, Roy-Chaudhury P, Cardi M, Kaiser TE, Thomas M, Woodle ES 2008. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids Clinical Transplantation, 22 2, 229-235Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA 2008. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgey in end-stage renal disease and transplant patients: a pilot study Clin Transplant, 22 3, 281-291Weimert NA, Alloway RR 2008. Monoclonal antibodies in solid organ transplantation Pharmaceutical Biotechnology: Fundamentals and Applications, , 365-375Whitaker I, Guggan EM, Alloway RR, Brown C, McGuire S, Woodle ES, Banis JC, Maldonado C, Barker JH 2008. Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons Journal of Plastic, Reconstructive and Aesthetic Surgery , 61 5, 481-492Vasilic D, Alloway RR, Barker JH, Furr A, Askcroft R, Banis JC Jr, Kon M, Woodle ES 2007. Risk assessment of immunosuppressive therapy in facial transplantation Plast Recontstr Surg, 120 3, 657-668Vasilic D, Alloway RR, Furr A, Ashcroft R, Kon M, Banis JC, Barker JH, Woodle ES 2007. Risk assessment of immunosuppressive therapy in facial transplantation Plastic and Reconstructive Surgery , 120 3, 657-668Weimert NA, Alloway RR 2007. Renal transplantation in high risk patients Drugs, 67 11, 1603-1627Weimert NA, DeRotte M, Alloway RR, Vinks AA, Woodle ES 2007. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications Ther Drug Monitor, 29 , 141Alexander JW, Metze TJ, Goodman HR, Cardi M, Austin J, GOel S, Safdar S, Huang S, Munda R, Fidler J, Buell JF, Hanaway MJ, Susskind B, Greenburg N, Trofe J, Alloway RR, Woodle ES 2006. Simultaneous corticosteroid and calcineurin inhibitor minimization European Society for Organ Transplantation, 19 , 295-302Alexander JW, Goodman HR, Alloway RR, Woodle ES 2005. Can immunonutrients reduce rejection rates in African Americans? Experimental and Clinical Transplantation, 2 , 349-350Alloway RR, Hanaway MF, Trofe J, Boardman R, Rogers CC, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2005. A prospective pilot study of early corticosteroid elimination under modern immunsuppression in patients at high immunologic risk: The Cincinnati experience Graft, 7 1, 10-11Alloway RR, Hanaway MF, Trofe J, Boardman R,Rogers CC, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2005. A prospective pilot study of early corticosteroid cessation in high immunologic risk patients: The Cincinnati Experience Transplant Proc, 37 , 802-803Boardman R, Trofe J, Alloway RR, Rogers CC, Roy-Chaudhury P, Cardi M, Buell JF, Hanaway M, Thomas MJ, Alexander JW, Munda R, Woodle ES 2005. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis Transplantation Proceedings, 37 , 817-818Boardman RE, Alexander JW, Alloway RR, Buell JF, Clippard M, Gupta M, Hanaway M, Merchen T, Metze T, Munda R, Peddi VR, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES 2005. African American renal transplant recipients benefit from early corticosteroid cessation under modern immunosuppression American Journal of Transplantation, 5 , 356-365Boardman RE, Alexander JW, Alloway RR, Buell JF, Clippard M, Gupta M, Hanaway M, Merchen T, Metze T, Munda R, Peddi VR, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES 2005. African American renal transplant recipients benefit from early corticosteroid cessation under modern immunosuppression Transplantation Proceedings, 37 , 814-816Buell JF, Beebe TM, Gross TG, Trofe J, Hanaway MJ, Alloway RR, First MR, Woodle ES 2005. United network for organ sharing publication on scientific registry of Transplant Recipients Central Nervous System Donor Cancer Transmission Data Transplantation, 79 5, 623Buell JF, Gross T, Alloway RR, Trofe J, Woodle ES 2005. Central Nervous System Tumors in Donors: Misdiagnosis carries a high morbidity and mortality Transplant Proc, 37 , 583-584Buell JF, Gross TG, Hanaway MH, Trofe J, Muthiak C, First MR, Alloway RR, Woodle ES 2005. Chemotherapy for PTLD: The Israel Penn International Transplant Tumor Registry Experience Transplantation Proceedings, 37 , 956-957Buell JF, Hanaway MJ, Thomas MJ, Alloway RR, Woodle ES 2005. Skin cancer following transplantation: The Israel Penn International Transplant Tumor Registry Experience Transplantation Proceedings, 37 , 962-963Buell JF, Hanaway MJ, Thomas MJ, Munda R, Alloway RR, First MR, Woodle ES 2005. Donor kidneys with small renal cell cancers: can they be transplanted? Transplant Proceedings, 37 , 581-582Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, WOodle ES 2005. De novo colorectal cancer: Five-year survival is markedly lower in transplant recipients compared to the general population Transplant Proceedings, 37 , 960-961Hanaway MJ, Roy-Chaudhury P, Buell JF, Thomas MJ, Munda R, Alloway RR, Ellison V, Rudich SM, Fisher L, Woodle ES 2005. Pilot study of early corticosteroid elimination after pancreas transplantation Transplant Proceedings, 37 , 1287-1288Rogers C, Alloway RR, Boardman R, Trofe J, Hanaway M, Alexander J, Roy-Chaudhury P, Buell J, Thomas M, Cardi M, Susskind B, Woodle ES 2005. Global Cardiovascular Risk under Early Steroid Cessation Decreases Progressively in the First Year Post Transplant Graft, 7 1, 38-39Rogers CC, Alloway RR, Boardman R, Trofe J, Hanaway MJ, Alexander JW, Roy-Chaudhury P, Buell JF, Thomas MJ, Susskind D, Woodle ES 2005. Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation Transplantation Proceedings, 37 , 812-813Rogers CC, Alloway RR, Hanaway M, Buell JF, Roy-Chaudhury P, Succop P, Woodle ES 2005. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression Transplant Proc, 37 , 800-801Rogers CC, Hanaway M, Alloway RR, Alexander JW, Boardman RE, Trofe J, Gupta M, Merchen T, Buell JF, Cardi M, Roy-Chaudhury P, Succop P, Woodle ES 2005. Corticosteroid avoidance ameliorates lymphocele formation and would healing complications associated with sirolimus therapy Transplant Proc, 37 , 795-797Rogers J, Stratta RJ, Lo A, Alloway RR 2005. Inferior late functional and metabolic outcomes in African American simultaneous kidney-pancreas recipients Transplant Proc, 37 8, 3552-3554Trofe J, Buell JH, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES 2005. The Israel Penn International Transplant Tumor Registry experience with 402 renal transplant recipients with post transplant lymphoproliferaitve disorder: Multivariate analysis of risk factors that influence survivial American Journal of Transplantation, 5 4 (pt 1), 775-780Woodle ES, Alloway RR, Hanaway MJ, Buell JF, Thomas MJ, Roy-Chaudhury P, Trofe J 2005. Early corticosteroid withdrawal under modern immunosuppression in renal transplantation Transplantation Proceedings, 37 , 798-799Woodle ES, Alloway RR, Succop P. Thomas M, Buell J, Tevar A, Munda R, Roy-Chuadhury P, Cardi M, Trofe J 2005. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression American Journal of Transplantation, 5 11, 2740-2744Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas MJ, Buell JF, ALexander JW, Roy-Chaudhury P, Succop P, Cardi M, Boardman R, Rogers CC 2005. Histocompatability testing predicts acute rejection risk in early corticosteroid withdrawal regimens Transplantation Proceedings, 37 , 809-811Alloway RR, Trofe J, Boardman R, Rogers CC, Hanaway MJ, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2004. A prospective pilot study of early corticosteroid elimination under modern immunosuppression on patients at high immunologic risk: The Cincinnati experience Graft, 7 1, 10-11Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Beebe T, Woodle ES, Buell JF 2004. Experience with 274 cardiac transplant recipients post-transplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry Transplantation, 11 , 1676-1682Buell JF, Beebe TM, Gross TG, Trofe J, Hanaway MJ, Alloway RR, First MR, Woodle ES 2004. Donor transmitted malignancies Ann Transplant, 9 1, 53-56Papaconstantinou HT, Sklow B, Hanaway MJ, Gross TG, Beebe TM, Trofe J, Alloway RR, Woodle ES, Buell JF 2004. Characteristics and survival patters of solid organ transplant patients developing de novo colon and rectal cancer Dis Colon Rectum, 47 11, 1898-1903Rogers J, Stratta RJ, Alloway RR, Lo A, Hodge EE and PIVOT Investigators 2004. African-American Ethnicity is no longer a risk factor for early adverse outcome in simultaneous kidney-pancreas transplant with contemporary immunosuppression Transplant Proceedings, 36 4, 1055-1057Stratta RJ, Alloway RR, Lo A, Hodge E 2004. Does surgical techniqu influence outcomes after simultaneous kidney-pancreas transplantation? Transplant Proceedings, 36 4, 1076-1077Stratta RJ, Alloway RR, Lo A, Hodge E and PIVOT Investigators 2004. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative-dosing regimen of Daclizumab Transplant Proc, 36 4, 1080-1081Trofe J, Beebe TM, Buell JF, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES 2004. Post-Transplant Malignancies Progress in Transplantation, 14 3, 193-200Trofe J, Buell JF, Woodle ES, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG 2004. Recurrence risk following organ transplantation in patients with a history of Hodgkin's disease or non-Hodgkin's lymphoma Transplantation, 78 7, 972-977Alloway RR, Isaacs R, Lake K, Hoyer P, First MR, Helderman H, Bunnapradist S, Leichtman A, Bennett W, Tejani A, Takemoto S 2003. Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants American Journal of Transplantation, 10 , 1211-1215Buell JF, Trofe J, Sethuraman G, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2003. Donors with central nervous system malignancies: are they truly safe? Transplantation, 76 2, 340-343Stratta RJ, Alloway RR, Hodge E, Lo A, PIVOT Investigators 2003. Two Dose Daclizumab Regimen Provides Superior Outcomes in Simultaneous Kidney/Pancreas Transplant Recipients: Primary Endpoint Analysis of a Multi-Center Randomized Study Transplantation, 75 8, 1260-1266Trofe J, Gaber LW, Stratta RJ, Shokouh-Amiri HS, Grewal HP, Vera SR, Reed L, Alloway RR, Lo A, Gaber AO 2003. Polyomavirus in kidney and kidney-pancreas transplant recipients Transplant Infectious Disease , 5 1, 21-28Trofe J, Gordon J, Roy-Chaudhury P, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalili K, Woodle ES 2003. Polyomavirus nephropathy in kidney and kidney-pancreas transplantation Journal of Neurovirology, 9 Suppl 2, 48Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES 2003. Basic and clinical research in polyomavirus nephropathy Exp Clin Transplant, 2 1, 162-173Trofe J, Roy-Chaudhury P, Gordon J, Mutema G, Cavallo T, Cardi M, Austin J, Goel S, Rogers C, Boardman R, Clippard M, Alloway RR, Alexander JW, Metze T, Goodman H, Hanaway MH, Munda R, Buell JF, Peddi VR, Safdar S, HUang S, Fidler J, Khalili K, Woodle ES 2003. Early Steroid Cessation/Avoidance Regimens are Associated with a Lower Incidence of Polyoma Virus Nephropathy Compared to Steroid Based Immunosuppression in Kidney Transplant Recipients Transplantation Review, 17 4, S52-S53Witherow BA, Roth GS, Carrozza MA, Freyberg RG, Kopke JE, Alloway RR, Buell JF, First MR, Gross TG, Hanaway MJ, Troge J, Woodle ES, Beebe TM 2003. The Israel Penn International Transplant Tumor Registry Proc AMIA Sympo, , 1053Woodle ES, Roy-Chaudhury P, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalil K, Gordon J, Trofe J 2003. Pathology of polyomavirus nephropathy in renal transplant recipients Journal of Neurovirology, 9 Suppl 2, 16Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker M, Alloway RR, Meibohm B 2003. The effect of CYP3A5 and MDR1 Polymorphis Expression on Cyclosporine Oral Disposition in Renal Transplant Patients The Journal of Clinical Pharmacology, 43 6, Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2002. Immunosuppression and Merkel Cell Cancer Transplant Proc, 34 5, 1780-1781Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2002. De novo breast cancer in renal transplant recipients Transplant Proc, 34 5, 1778-1789Honaker MR, Stratta RJ, Lo A, Egidi MF, Amiri S, Grewal HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO 2002. Impact of HCV status in pancreas transplantation: a case controlled study Clin Transplant, 16 , 1-9Honaker MR, Stratta RJ, Lo A, Egidi MF, Amiri S, Grewal HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO 2002. Impact of hepatitis C virus status and pancreas transplantation: A case controlled study Clin Transplant, 16 4, 243-251Lo A, Alloway RR 2002. Strategies to Reduce Toxicities and Improve Outcomes in Renal Transplant Recipients Pharmacotherapy, 22 3, 316-328Lo A, Stratta RJ, Trofe J, Norwood J, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Gaber AO 2002. Rhodococcus Equi Pulmonary Infection in a Pancreas Alone Transplant Recipient: Consequence of Intense Immunosuppression Transplant Infectious Disease , 4 , 46-51Stratta RJ, Alloway RR, Hodge E, Lo A for the PIVOT study group 2002. A multicenter, open-label, comparative trial of two Daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis Clin Transplant, 16 1, 60-68Stratta RJ, Alloway RR, Lo A, Hodge E 2002. A multicenter trial of two dosing strategies versis no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis Transplant Proc, 34 5, 1903-1905Trofe J, Cavallo TC, First MR, Weiskittel P, Peddi VR, Roy-Chaudhury P, Alloway RR, Safdhar S, Buell JF, Hanaway MJ, Woodle ES 2002. Polyomavirus in kidney and kidney pancreas transplantation: a defined protocol for immunosuppression reduction and histologc monitoring Transplant Proc, 34 5, 1788-1789Trofe J, Stratta RJ, Egidi MF, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Honaker M, hardinger K, Alloway RR, Gaber AO 2002. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single center experience Clin Transplant, 7 Suppl 16, 34-44Buell JF, Trofe J, Hanaway MJ, Rilo H, Alloway RR, Beebe T, First MR, Woodle ES 2001. Transmisison of Donor Cancer into Cardio-Thoracic Transplant Recipients Surgery, 130 , 660-668Buell JF, Trofe J, Hanaway MJ, Rilo H, Alloway RR, Beebe T, First MR, Woodle ES 2001. Transmission of Donor Cancer into Cardio-Thoracic Transplant Recipients Surgery, 130 , 660Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera SR, Grewal HP, Alloway RR, Gaber AO 2001. Post Transplant Lymphoproliferative Disorders: A Single Center Experience Transplant Proceedings, 33 1-2, 1838-1839Hardinger KL, Stratta RJ, Egidi MF, Amiri MH, Grewal HP, Honaker MR, Vera SR, Alloway RR, Gaber LW, Gaber AO 2001. Renal Allograft Outcomes in African-American versus Caucasian Transplant Recipients in the Tacrolimus Era Surgery, 130 , 738-748Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO 2001. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil, and steroids in simultenous kidney-pancreas transplantation Transpl Int, 14 6, 396-404Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO 2001. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation Transplant Proc, 33 1-2, 1701-1703Lo A, Stratta RJ, Egidi MF, Kizilizik TA, Amiri MH, Grewal HP, Alloway RR, Trofe J, Gaber AO 2001. Ganciclovir Prophylaxis for CMV Infection in Simultaneous Kidney-Pancreas Transplant Recipients Receiving Tacrolimus, Mycophenolate Mofetil, and Prednisone Transplant Proc, 33 1-2, 1768-1769Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO 2001. Outcome of simultaneous kidney-pancreas transplantation in African-American recipients: a case control study Transplant Proc, 33 1-2, 1675-1677Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO 2001. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus mycophenolate mofetil, and prednisone with ganciclovir prophylaxis Transplant Infectious Disease , 3 , 8-15Lo A, Stratta RJ, Hathaway DK, Egidi MF, Amiri MH, Grewal HP, Winsett RP, Trofe J, Alloway RR, Gaber AO 2001. Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric vs. systemic-bladder drainage American Journal of Kidney Diseases, 38 , 132-143Lo A, Stratta RJ, Hathaway DK, Egidi MF, Amiri MH, Grewal HP, Winsett RP, Trofe J, Alloway RR, Gaber AO 2001. Long term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage Transplant Proc, 33 1-2, 1684-1686Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RH, Nezakatgoo N, Trofe J, Alloway RR, Gaber AO 2001. The importance of early prevention of renal dysfunction in liver transplant recipients Transplant Proc, 33 1-2, 1399-4000Stratta RJ, Alloway RR, Lo A, Hodge E 2001. A multicenter trial of two Daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis Transplant Proc, 33 1-2, 1692-1693Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Alloway RR, Hathaway DK, Gaber LW 2001. Nine-year experience with 126 pancreas transplants with portal-enteric drainage Transplant Proc, 33 1-2, 1687-1688Trofe J, Reddy KS, Stratta RJ, Flax SD, Somerville KT, Alloway RR, Egidi MF, Shokouh-Amiri MH, Gaber AO 2001. Human granulocytic ehrlichiosis in pancreas transplant recipients Transplant Infectious Disease , 3 1, 34-39Tujeta S, Alloway RR, Johnson JA, Gaber AO 2001. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients Transplantation, 71 , 1303-1307Winset RP, Stratta RJ, Alloway RR, Wicks MN, Hathaway DK 2001. Immunusuppressant side effect profile does not differ between organ transplant tupes Clin Transplant, 15 Suppl 6, 46-50Hurst GC, Alloway RR, Somerville KT, Gaber AO, Stratta RJ 2000. Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension Clin Transplant, 14 , 42-47Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO 2000. Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: A cas control study Clin Transplantation, 14 , 572-579Reddy KS, Stratta RJ, Shokouh-Amiri MH, Alloway RR, Somerville T, Egidi MF, Gaber AO 2000. Simultaneous kidney-pancreas transplantation without antilymphocyte induction Ann Surg, 69 , 49-54Alloway RR 1999. Generic immunosuppressant use in solid organ transplantation Transplant Proc, 31 , 2S-5SAlloway RR, Somerville TK 1999. Transplantation: Solid Organ. Basic Bibliographies Hospital Pharmacy, 34 , 379Alloway RR, Somerville TK 1999. Transplantation Immunusuppression. Basic Bibliographies. Hospital Pharmacy, 34, 380Gaston R, Alloway RR, Gaber AO, Schroeder TJ, Irish WD, Canafax DM, First MR 1999. Pharmacokinetics and safety evaluation of SangCya vs Neoral or Sandimmune in stable retransplant recipients Transplant Proc, 31 , 326-327Meier-Kriesch HU, Alloway RR, Gaber AO, Canafax D, Kaplan B 1999. A limited sampling strategy (LSS) for the estimation of 12-hour SangCya and Neoral AUCs in renal transplant recipients J Clin Pharmacol, 39 , 166-167Reddy KS, Stratta RJ, Shokouh-Amiri MH, Alloway RR, Egidi MF, Gaber AO 1999. Surgical complications after pancreas transplantation with portal-enteric drainage J Am Coll Surg, 189 , 305-313Stratta RJ, Gaber AO, Shokouh-Amiri MH, Reddy KS, Alloway RR, Egidi MF, Grewal HP, Gaber LW, Hathaway D 1999. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction Ann Surg, 229 , 709-712Stratta RJ< Gaber AO, Shoukouh-Amiri MH, Reddy S, Alloway RR, Egidi MF, Grewal HP, Gaber LW, Hathaway DK 1999. Evolution in Pancreas Transplantation Techniques: Simultaneous Kidney-Pancreas Transplantation Using Portal-Enteric Drainage Without Antilymphocyte Induction Ann Surg, 229 , 701-712Alloway RR, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO 1998. Bioequivalence comparison of Snadimmune and Neoral versus Sang-35 cyclosporine in kidney transplant recipients J Am Soc Nephrol, 8 , 672AFirst MR, Alloway RR, Schroeder TJ 1998. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral Clin Transplantation, 12 , 518-524Hurst G, Alloway RR, Hathaway D, Somerville T, Hughes T, Gaber AO 1998. Stabilization of bone mass after renal transplant with preemptive care Transplant Proc, 30 , 1327-1328Somerville T, Hurst G, Alloway RR, Gaber AO, Shokouh-Amiri MH, Stratta R 1998. Superior efficacy of oral gancyclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients Transplant Proc, 30 , 1546-1548Stratta RJ, Alloway RR 1998. Pancreas transplantation for diabetes mellitus: A guide to recipient selection and optimum immunosuppression Biodrugs, 10 5, 347-357Winsett RP and the Posttransplant Quality of Life Intervention Study Group 1998. Posttransplant quality of life: a decade of descriptive studies leading to practice interventions J Transplant Coordination, 8 , 236-240Gaber LW, Moore LW, Reed L, Russell W, Alloway R, Hathaway D, Shokough-Amiri MH, Gaber AO 1997. Renal histology with varying FK 506 blood levels Transplant Proc, 29 , 186Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO 1996. Conversion from Cyclosporine to tacrolimus in kidney, kidney/pancreas and pancreas alone transplant recipients: the Memphis Experience Transplant Proc, 28 , 995-997Elmer D, Nymann T, Hathaway D, Alloway RR, Gaber AO 1996. Use of FK-506 immunosuppression in pancreas transplant J Transplant Coordination, 6 , 122-127Gaberr LW, Moorle LW, Alloway RR, Flax S, Schroeder T, Amiri H, Gaber AO 1996. Correlation between BANFF scores of acute renal rejection scores and reversal of rejection Kidney Int, 49 , 481-497Moore LW, Alloway RR, Smith SO, Acchiardio SR, Gaber AO 1996. Clinical obsevations of metabolic changes occurring in renal transplant recipients receiving ketoconazole Transplantation, 61 , 537-541Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO 1996. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation Clin Transplantation, 10 , 633-667Self T, Alloway R 1996. Treatment of Rhinitis J Am Acad Nurse Pract, 8 , 135-144Gaber LW, Moore LW, Alloway RR, Flax S, Gaber AO 1995. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection Transplant Proc, 27 , 1019Gaber LW, Moore LW, Alloway RR, Shokouh-Amiri MH, Vera SR, Gaber AO 1995. Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts Transplantation, 60 , 334-339Alloway RR, Kotb M, Hathaway D, Ohman M, Gaber AO 1994. Pharmacokinetic Profile of OKT3 in Renal Transplant Recipients Receiving Standard and Low Dose OKT3 for Induction Immunosuppression Transplantation, 58 , 249-253Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1993. Results of Prospective, Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy Transplant Proc, 25 1, 550-552Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1993. Results of a Prospective, Randomized, Double-Blind Study Comparing Standard versus Low Dose OKT3 Induction Therapy American Journal of Kidney Diseases, 22 36-43, Self T, Heilker G, Alloway RR, Kelso T, Abou-Shala N 1993. Reassessing the Therapeutic Range for Theophyilline on Laboratory Report Forms: The Importance of 5-15 mcg/ml Pharmacotherapy, 13 6, 590-594Alloway RR, Kotb M, Gaber L, Boskey F, Gaber AO 1992. Standard versus Low Dose OKT3 Induction of Cadaveric Renal Transplants: Compairson of Outcome Data versus OKT3 Dose and Serum LEvels Clin Transplantation, 46 , 468-472Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1992. Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients Scientia, 1 6, Kelso TM, Alloway RR, Self TH 1992. Asthma Patient Education Journal of Pharmacy Practice, 5 , 186-196Busque S, Cantarovich M, Mulgonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators 12-2011. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation Am J Transplant, 11 12, 2675-2684Trofe-Clark J, Gabardi S, McDevitt-Potter L, Alloway RR 12-17-2011. Immunosuppression. Generic Drugs and the FDA Am J Transplant, , Bruce DS, Sollinger HW, Humar A, Sutherland DER, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ 11-27-2001. Multicenter Survey of Daclizumab Induction in Simultaneous Kidney-Pancreas Transplant Recipients Transplantation, 72 10, 1637-1643Buell JF, Alloway RR, Woodle ES 10-2006. How can donors with a previous malignancy be evaluated? J Hepatol, 45 4, 503-507Rogers J, Stratta RJ, Lo A, Alloway RR 10-2005. Impact of metabolic syndrome on long-term outcomes in simultaneous kidney-pancreas transplantation Transplant Proc, 37 8, 3549-3551Stratta RJ, Alloway RR, Lo A, Hodge E 10-2005. Risk factors and outcomes analyses of a prospective, randomized, multicenter trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients Transplant Proc, 37 8, 3527-3530Winsett RP, Arheart K, Stratta RJ, Alloway RR, Wicks MN, Gaber AO, Hathaway DK 09-2004. Evaluation of an immunosuppressant side effect instrument Prog Transplant, 14 3, 210-216Honaker MR, Amiri S, Vera SR, Alloway RR, Grewal HP, Hardinger KL, Kizilisik TA, Bagous T, Trofe J, Stratta RJ, Egidi MF, Gaber AO 09-2002. Evolving experience of HBV prophylaxis in liver transplantation Transplant Infectious Disease , 4 3, 137-143Self T, Alloway R 09-1993. Nonsedating Antihistamines Pharmacy Newsletter, , Alloway RR, Dupuis R, Gabardi S, Kaiser TE, Taber DJ, Tichy EM, Weimert-Pilch NA; American Society of Transplantation Transplant Pharmacy Community of Practice and the American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network 08-2011. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team Am J Transplant, 11 8, 1576-1583Woodle ES, Alloway RR, Girnita A 08-2011. Proteasome inhibitor treatment of antibody-mediated allograft rejection Curr Opin Organ Transplant, 16 4, 434-438Buell JF, Thomas GG, Thomas MJ, Neff G, Muthiah C, Alloway RR, Woodle ES 08-2006. Malignancy in pediatric transplant recipients Seminars in Pediatric Surgery, 15 3, 179-187Gaber AO, Mulgaonkar S, Kahan BD, Woodle ES, Alloway RR, Bajjoka I, Jensik S, Klintmalm GB, Patton PR, Wiseman A, Lipshutz G, Kupiec-Weglinski J, Gaber LW, Katz E, Irish W, Squiers EC, Hemmerich S 07-2011. YSPSL (rPSGL-Ig) for improvement of early renal allograft function; a double-blind, placebo-controlled, multi-center Phase IIa study Clin Transplant, 25 4, 523-533Rogers CC, Alloway RR, Buell JF, Boardman R, Aelxander JW, Cardi M, Roy-Chaudhury P, First MR, Succop P, Munda R, Woodle ES 07-15-2005. Body weight alterations under early coticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression Transplantation, 80 1, 26-33Alloway RR, Steinburg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsh J, Martas A, Zaltzman J, Wisemandel K, Fitzsimmons W, First MR 06-27-2007. Two years postconversion from a prograf-based regimen to a once daily tacrolimus extended-release formulation in stable kidney transplant recipients Transplantation, 83 12, 1648-1651Florman S, Alloway RR, Kalayoglu M, Punch J, Bak T, Melancon J, Klintmalm G, Busque S, Charlton M, Lake J, Dhadda S, Wisemandle K, Wirth M, Fitzsimmons W, Holman J, First MR 06-27-2007. Once daily tacrolimus extended release formulation: experience at 2 years post conversion from a Prograf-based in stable liver transplant recipients Transplantation, 83 12, 1639-1642Reddy KS, Stratta RJ, Alloway RR, Lo A, Hodge EE; PIVOT Study Group 05-2004. The impact of delayed graft function of the kidney on the pancreas allograft in simultaneous kidney-pancreas transplantation Transplant Proc, 36 4, 1078-1079Stratta RJ, Alloway RR, Hodge E, Lo A, PIVOT Investigators 05-2004. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients Transplant Proc, 36 4, 1082-1083First MR, Alloway RR, Fisher RA, Pan SH, Lopez R, Renlund D, Schnitzler M, Gaber AO 05-2000. Generic drug substitution in transplantation: examples from the epic of Cyclosporine development Dialysis and Transplantation, 29 5, 260-267Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES 04-2004. Polyomavirus in Solid Organ Transplantation Progress in Transplantation, 14 2, 130-140Vasilic D, rteynolds CC, Cunningham M, Furr A, Storey B, Banis JC, Wiggins O, Maldonado C, Alloway RR, Kon M, Barker JH 03-2008. Plastic surgeon's risk acceptance in facial transplantation Plast Recontstr Surg, 121 3, 41e-48eFlorman S, Alloway RR, Kalayoglu M, Lake K, Bak T, Klein A, Klintmalm G, Busque S, Brandenhagen D, Lake J, Widemandle K, Fitzsimmons W, First MR 03-2005. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen Transplant Proc, 37 2, 1211-1213Lo A, Stratta RJ, Alloway RR, Hodge EE; PIVOT Study Group 03-2005. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation Transplant Proc, 37 2, 1289-1290Walker JK, Alloway RR, Roy-Chaudhury P, Mogilishetty G, Cardi M, Weimert NA, Rike AH, First MR, Woodle ES 02-15-2006. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in HLA identical live donor renal transplantation Transplantation, 87 3, 408-414Aull MJ, Buell JF, Peddi VR, Trode J, Beebe TM, Hanaway MH, Roy-Chaudhury P, Alloway RR, First MR, Woodle ES; Israel Penn International Transplant Tumor Registry 01-2002. MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report form the Israel Penn International Transplant Tumor Registry with a review of published literature Transplantation, 75 2, 225-228Alloway RR 01-1994. Spotlight of Heparin Dosing. Drug Information Update, Allied Pharmacy Management Inc, ,
Sadaka B, Alloway RR, Shields AR, Schmidt N, Woodle ES 2012. Proteasome inhibition for antibody mediated allograft rejection Seminars in Hematology, , Schmidt N, Alloway RR, Walsh CC, Sadaka B, Wall A, Shields AR, Woodle ES 2012. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients Transplantation, , Sadaka B, Alloway RR, Woodle ES 2011. Clinical and investigational use of proteasome inhibitors for transplant rejection Expert Opinion on Investigational Drugs, 20 11, 1535-1542van Hooff JP, Alloway RR, Trunecka P, Mourad M 2011. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de nove kidney, liver, and heart studies Clin Transplant, 25 1, Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P 2011. Proteasome inhibitor therapy for antibody-mediated rejection Pediatric Transplantation, 15 6, 548-556Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Brown E, Woodle ES 2009. Proteasome inhibition reduces donor-specific antibody levels Transplant Proceedings, 41 1, 105-107Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Brown E, Woodle ES 2008. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection Transplantation, 86 , 1754-1761Rike AH, Mogilishetty G, Alloway RR, Succop P, Roy-Chaudhury P, Cardi M, Kaiser TE, Thomas M, Woodle ES 2008. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids Clinical Transplantation, 22 2, 229-235Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA 2008. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgey in end-stage renal disease and transplant patients: a pilot study Clin Transplant, 22 3, 281-291Weimert NA, Alloway RR 2008. Monoclonal antibodies in solid organ transplantation Pharmaceutical Biotechnology: Fundamentals and Applications, , 365-375Whitaker I, Guggan EM, Alloway RR, Brown C, McGuire S, Woodle ES, Banis JC, Maldonado C, Barker JH 2008. Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons Journal of Plastic, Reconstructive and Aesthetic Surgery , 61 5, 481-492Vasilic D, Alloway RR, Barker JH, Furr A, Askcroft R, Banis JC Jr, Kon M, Woodle ES 2007. Risk assessment of immunosuppressive therapy in facial transplantation Plast Recontstr Surg, 120 3, 657-668Vasilic D, Alloway RR, Furr A, Ashcroft R, Kon M, Banis JC, Barker JH, Woodle ES 2007. Risk assessment of immunosuppressive therapy in facial transplantation Plastic and Reconstructive Surgery , 120 3, 657-668Weimert NA, Alloway RR 2007. Renal transplantation in high risk patients Drugs, 67 11, 1603-1627Weimert NA, DeRotte M, Alloway RR, Vinks AA, Woodle ES 2007. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications Ther Drug Monitor, 29 , 141Alexander JW, Metze TJ, Goodman HR, Cardi M, Austin J, GOel S, Safdar S, Huang S, Munda R, Fidler J, Buell JF, Hanaway MJ, Susskind B, Greenburg N, Trofe J, Alloway RR, Woodle ES 2006. Simultaneous corticosteroid and calcineurin inhibitor minimization European Society for Organ Transplantation, 19 , 295-302Alexander JW, Goodman HR, Alloway RR, Woodle ES 2005. Can immunonutrients reduce rejection rates in African Americans? Experimental and Clinical Transplantation, 2 , 349-350Alloway RR, Hanaway MF, Trofe J, Boardman R, Rogers CC, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2005. A prospective pilot study of early corticosteroid elimination under modern immunsuppression in patients at high immunologic risk: The Cincinnati experience Graft, 7 1, 10-11Alloway RR, Hanaway MF, Trofe J, Boardman R,Rogers CC, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2005. A prospective pilot study of early corticosteroid cessation in high immunologic risk patients: The Cincinnati Experience Transplant Proc, 37 , 802-803Boardman R, Trofe J, Alloway RR, Rogers CC, Roy-Chaudhury P, Cardi M, Buell JF, Hanaway M, Thomas MJ, Alexander JW, Munda R, Woodle ES 2005. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis Transplantation Proceedings, 37 , 817-818Boardman RE, Alexander JW, Alloway RR, Buell JF, Clippard M, Gupta M, Hanaway M, Merchen T, Metze T, Munda R, Peddi VR, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES 2005. African American renal transplant recipients benefit from early corticosteroid cessation under modern immunosuppression American Journal of Transplantation, 5 , 356-365Boardman RE, Alexander JW, Alloway RR, Buell JF, Clippard M, Gupta M, Hanaway M, Merchen T, Metze T, Munda R, Peddi VR, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES 2005. African American renal transplant recipients benefit from early corticosteroid cessation under modern immunosuppression Transplantation Proceedings, 37 , 814-816Buell JF, Beebe TM, Gross TG, Trofe J, Hanaway MJ, Alloway RR, First MR, Woodle ES 2005. United network for organ sharing publication on scientific registry of Transplant Recipients Central Nervous System Donor Cancer Transmission Data Transplantation, 79 5, 623Buell JF, Gross T, Alloway RR, Trofe J, Woodle ES 2005. Central Nervous System Tumors in Donors: Misdiagnosis carries a high morbidity and mortality Transplant Proc, 37 , 583-584Buell JF, Gross TG, Hanaway MH, Trofe J, Muthiak C, First MR, Alloway RR, Woodle ES 2005. Chemotherapy for PTLD: The Israel Penn International Transplant Tumor Registry Experience Transplantation Proceedings, 37 , 956-957Buell JF, Hanaway MJ, Thomas MJ, Alloway RR, Woodle ES 2005. Skin cancer following transplantation: The Israel Penn International Transplant Tumor Registry Experience Transplantation Proceedings, 37 , 962-963Buell JF, Hanaway MJ, Thomas MJ, Munda R, Alloway RR, First MR, Woodle ES 2005. Donor kidneys with small renal cell cancers: can they be transplanted? Transplant Proceedings, 37 , 581-582Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, WOodle ES 2005. De novo colorectal cancer: Five-year survival is markedly lower in transplant recipients compared to the general population Transplant Proceedings, 37 , 960-961Hanaway MJ, Roy-Chaudhury P, Buell JF, Thomas MJ, Munda R, Alloway RR, Ellison V, Rudich SM, Fisher L, Woodle ES 2005. Pilot study of early corticosteroid elimination after pancreas transplantation Transplant Proceedings, 37 , 1287-1288Rogers C, Alloway RR, Boardman R, Trofe J, Hanaway M, Alexander J, Roy-Chaudhury P, Buell J, Thomas M, Cardi M, Susskind B, Woodle ES 2005. Global Cardiovascular Risk under Early Steroid Cessation Decreases Progressively in the First Year Post Transplant Graft, 7 1, 38-39Rogers CC, Alloway RR, Boardman R, Trofe J, Hanaway MJ, Alexander JW, Roy-Chaudhury P, Buell JF, Thomas MJ, Susskind D, Woodle ES 2005. Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation Transplantation Proceedings, 37 , 812-813Rogers CC, Alloway RR, Hanaway M, Buell JF, Roy-Chaudhury P, Succop P, Woodle ES 2005. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression Transplant Proc, 37 , 800-801Rogers CC, Hanaway M, Alloway RR, Alexander JW, Boardman RE, Trofe J, Gupta M, Merchen T, Buell JF, Cardi M, Roy-Chaudhury P, Succop P, Woodle ES 2005. Corticosteroid avoidance ameliorates lymphocele formation and would healing complications associated with sirolimus therapy Transplant Proc, 37 , 795-797Rogers J, Stratta RJ, Lo A, Alloway RR 2005. Inferior late functional and metabolic outcomes in African American simultaneous kidney-pancreas recipients Transplant Proc, 37 8, 3552-3554Trofe J, Buell JH, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES 2005. The Israel Penn International Transplant Tumor Registry experience with 402 renal transplant recipients with post transplant lymphoproliferaitve disorder: Multivariate analysis of risk factors that influence survivial American Journal of Transplantation, 5 4 (pt 1), 775-780Woodle ES, Alloway RR, Hanaway MJ, Buell JF, Thomas MJ, Roy-Chaudhury P, Trofe J 2005. Early corticosteroid withdrawal under modern immunosuppression in renal transplantation Transplantation Proceedings, 37 , 798-799Woodle ES, Alloway RR, Succop P. Thomas M, Buell J, Tevar A, Munda R, Roy-Chuadhury P, Cardi M, Trofe J 2005. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression American Journal of Transplantation, 5 11, 2740-2744Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas MJ, Buell JF, ALexander JW, Roy-Chaudhury P, Succop P, Cardi M, Boardman R, Rogers CC 2005. Histocompatability testing predicts acute rejection risk in early corticosteroid withdrawal regimens Transplantation Proceedings, 37 , 809-811Alloway RR, Trofe J, Boardman R, Rogers CC, Hanaway MJ, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES 2004. A prospective pilot study of early corticosteroid elimination under modern immunosuppression on patients at high immunologic risk: The Cincinnati experience Graft, 7 1, 10-11Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Beebe T, Woodle ES, Buell JF 2004. Experience with 274 cardiac transplant recipients post-transplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry Transplantation, 11 , 1676-1682Buell JF, Beebe TM, Gross TG, Trofe J, Hanaway MJ, Alloway RR, First MR, Woodle ES 2004. Donor transmitted malignancies Ann Transplant, 9 1, 53-56Papaconstantinou HT, Sklow B, Hanaway MJ, Gross TG, Beebe TM, Trofe J, Alloway RR, Woodle ES, Buell JF 2004. Characteristics and survival patters of solid organ transplant patients developing de novo colon and rectal cancer Dis Colon Rectum, 47 11, 1898-1903Rogers J, Stratta RJ, Alloway RR, Lo A, Hodge EE and PIVOT Investigators 2004. African-American Ethnicity is no longer a risk factor for early adverse outcome in simultaneous kidney-pancreas transplant with contemporary immunosuppression Transplant Proceedings, 36 4, 1055-1057Stratta RJ, Alloway RR, Lo A, Hodge E 2004. Does surgical techniqu influence outcomes after simultaneous kidney-pancreas transplantation? Transplant Proceedings, 36 4, 1076-1077Stratta RJ, Alloway RR, Lo A, Hodge E and PIVOT Investigators 2004. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative-dosing regimen of Daclizumab Transplant Proc, 36 4, 1080-1081Trofe J, Beebe TM, Buell JF, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES 2004. Post-Transplant Malignancies Progress in Transplantation, 14 3, 193-200Trofe J, Buell JF, Woodle ES, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG 2004. Recurrence risk following organ transplantation in patients with a history of Hodgkin's disease or non-Hodgkin's lymphoma Transplantation, 78 7, 972-977Alloway RR, Isaacs R, Lake K, Hoyer P, First MR, Helderman H, Bunnapradist S, Leichtman A, Bennett W, Tejani A, Takemoto S 2003. Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants American Journal of Transplantation, 10 , 1211-1215Buell JF, Trofe J, Sethuraman G, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2003. Donors with central nervous system malignancies: are they truly safe? Transplantation, 76 2, 340-343Stratta RJ, Alloway RR, Hodge E, Lo A, PIVOT Investigators 2003. Two Dose Daclizumab Regimen Provides Superior Outcomes in Simultaneous Kidney/Pancreas Transplant Recipients: Primary Endpoint Analysis of a Multi-Center Randomized Study Transplantation, 75 8, 1260-1266Trofe J, Gaber LW, Stratta RJ, Shokouh-Amiri HS, Grewal HP, Vera SR, Reed L, Alloway RR, Lo A, Gaber AO 2003. Polyomavirus in kidney and kidney-pancreas transplant recipients Transplant Infectious Disease , 5 1, 21-28Trofe J, Gordon J, Roy-Chaudhury P, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalili K, Woodle ES 2003. Polyomavirus nephropathy in kidney and kidney-pancreas transplantation Journal of Neurovirology, 9 Suppl 2, 48Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES 2003. Basic and clinical research in polyomavirus nephropathy Exp Clin Transplant, 2 1, 162-173Trofe J, Roy-Chaudhury P, Gordon J, Mutema G, Cavallo T, Cardi M, Austin J, Goel S, Rogers C, Boardman R, Clippard M, Alloway RR, Alexander JW, Metze T, Goodman H, Hanaway MH, Munda R, Buell JF, Peddi VR, Safdar S, HUang S, Fidler J, Khalili K, Woodle ES 2003. Early Steroid Cessation/Avoidance Regimens are Associated with a Lower Incidence of Polyoma Virus Nephropathy Compared to Steroid Based Immunosuppression in Kidney Transplant Recipients Transplantation Review, 17 4, S52-S53Witherow BA, Roth GS, Carrozza MA, Freyberg RG, Kopke JE, Alloway RR, Buell JF, First MR, Gross TG, Hanaway MJ, Troge J, Woodle ES, Beebe TM 2003. The Israel Penn International Transplant Tumor Registry Proc AMIA Sympo, , 1053Woodle ES, Roy-Chaudhury P, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalil K, Gordon J, Trofe J 2003. Pathology of polyomavirus nephropathy in renal transplant recipients Journal of Neurovirology, 9 Suppl 2, 16Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker M, Alloway RR, Meibohm B 2003. The effect of CYP3A5 and MDR1 Polymorphis Expression on Cyclosporine Oral Disposition in Renal Transplant Patients The Journal of Clinical Pharmacology, 43 6, Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2002. Immunosuppression and Merkel Cell Cancer Transplant Proc, 34 5, 1780-1781Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES 2002. De novo breast cancer in renal transplant recipients Transplant Proc, 34 5, 1778-1789Honaker MR, Stratta RJ, Lo A, Egidi MF, Amiri S, Grewal HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO 2002. Impact of HCV status in pancreas transplantation: a case controlled study Clin Transplant, 16 , 1-9Honaker MR, Stratta RJ, Lo A, Egidi MF, Amiri S, Grewal HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO 2002. Impact of hepatitis C virus status and pancreas transplantation: A case controlled study Clin Transplant, 16 4, 243-251Lo A, Alloway RR 2002. Strategies to Reduce Toxicities and Improve Outcomes in Renal Transplant Recipients Pharmacotherapy, 22 3, 316-328Lo A, Stratta RJ, Trofe J, Norwood J, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Gaber AO 2002. Rhodococcus Equi Pulmonary Infection in a Pancreas Alone Transplant Recipient: Consequence of Intense Immunosuppression Transplant Infectious Disease , 4 , 46-51Stratta RJ, Alloway RR, Hodge E, Lo A for the PIVOT study group 2002. A multicenter, open-label, comparative trial of two Daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis Clin Transplant, 16 1, 60-68Stratta RJ, Alloway RR, Lo A, Hodge E 2002. A multicenter trial of two dosing strategies versis no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis Transplant Proc, 34 5, 1903-1905Trofe J, Cavallo TC, First MR, Weiskittel P, Peddi VR, Roy-Chaudhury P, Alloway RR, Safdhar S, Buell JF, Hanaway MJ, Woodle ES 2002. Polyomavirus in kidney and kidney pancreas transplantation: a defined protocol for immunosuppression reduction and histologc monitoring Transplant Proc, 34 5, 1788-1789Trofe J, Stratta RJ, Egidi MF, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Honaker M, hardinger K, Alloway RR, Gaber AO 2002. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single center experience Clin Transplant, 7 Suppl 16, 34-44Buell JF, Trofe J, Hanaway MJ, Rilo H, Alloway RR, Beebe T, First MR, Woodle ES 2001. Transmisison of Donor Cancer into Cardio-Thoracic Transplant Recipients Surgery, 130 , 660-668Buell JF, Trofe J, Hanaway MJ, Rilo H, Alloway RR, Beebe T, First MR, Woodle ES 2001. Transmission of Donor Cancer into Cardio-Thoracic Transplant Recipients Surgery, 130 , 660Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera SR, Grewal HP, Alloway RR, Gaber AO 2001. Post Transplant Lymphoproliferative Disorders: A Single Center Experience Transplant Proceedings, 33 1-2, 1838-1839Hardinger KL, Stratta RJ, Egidi MF, Amiri MH, Grewal HP, Honaker MR, Vera SR, Alloway RR, Gaber LW, Gaber AO 2001. Renal Allograft Outcomes in African-American versus Caucasian Transplant Recipients in the Tacrolimus Era Surgery, 130 , 738-748Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO 2001. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil, and steroids in simultenous kidney-pancreas transplantation Transpl Int, 14 6, 396-404Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO 2001. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation Transplant Proc, 33 1-2, 1701-1703Lo A, Stratta RJ, Egidi MF, Kizilizik TA, Amiri MH, Grewal HP, Alloway RR, Trofe J, Gaber AO 2001. Ganciclovir Prophylaxis for CMV Infection in Simultaneous Kidney-Pancreas Transplant Recipients Receiving Tacrolimus, Mycophenolate Mofetil, and Prednisone Transplant Proc, 33 1-2, 1768-1769Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO 2001. Outcome of simultaneous kidney-pancreas transplantation in African-American recipients: a case control study Transplant Proc, 33 1-2, 1675-1677Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO 2001. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus mycophenolate mofetil, and prednisone with ganciclovir prophylaxis Transplant Infectious Disease , 3 , 8-15Lo A, Stratta RJ, Hathaway DK, Egidi MF, Amiri MH, Grewal HP, Winsett RP, Trofe J, Alloway RR, Gaber AO 2001. Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric vs. systemic-bladder drainage American Journal of Kidney Diseases, 38 , 132-143Lo A, Stratta RJ, Hathaway DK, Egidi MF, Amiri MH, Grewal HP, Winsett RP, Trofe J, Alloway RR, Gaber AO 2001. Long term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage Transplant Proc, 33 1-2, 1684-1686Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RH, Nezakatgoo N, Trofe J, Alloway RR, Gaber AO 2001. The importance of early prevention of renal dysfunction in liver transplant recipients Transplant Proc, 33 1-2, 1399-4000Stratta RJ, Alloway RR, Lo A, Hodge E 2001. A multicenter trial of two Daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis Transplant Proc, 33 1-2, 1692-1693Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Alloway RR, Hathaway DK, Gaber LW 2001. Nine-year experience with 126 pancreas transplants with portal-enteric drainage Transplant Proc, 33 1-2, 1687-1688Trofe J, Reddy KS, Stratta RJ, Flax SD, Somerville KT, Alloway RR, Egidi MF, Shokouh-Amiri MH, Gaber AO 2001. Human granulocytic ehrlichiosis in pancreas transplant recipients Transplant Infectious Disease , 3 1, 34-39Tujeta S, Alloway RR, Johnson JA, Gaber AO 2001. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients Transplantation, 71 , 1303-1307Winset RP, Stratta RJ, Alloway RR, Wicks MN, Hathaway DK 2001. Immunusuppressant side effect profile does not differ between organ transplant tupes Clin Transplant, 15 Suppl 6, 46-50Hurst GC, Alloway RR, Somerville KT, Gaber AO, Stratta RJ 2000. Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension Clin Transplant, 14 , 42-47Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO 2000. Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: A cas control study Clin Transplantation, 14 , 572-579Reddy KS, Stratta RJ, Shokouh-Amiri MH, Alloway RR, Somerville T, Egidi MF, Gaber AO 2000. Simultaneous kidney-pancreas transplantation without antilymphocyte induction Ann Surg, 69 , 49-54Alloway RR 1999. Generic immunosuppressant use in solid organ transplantation Transplant Proc, 31 , 2S-5SAlloway RR, Somerville TK 1999. Transplantation: Solid Organ. Basic Bibliographies Hospital Pharmacy, 34 , 379Alloway RR, Somerville TK 1999. Transplantation Immunusuppression. Basic Bibliographies. Hospital Pharmacy, 34, 380Gaston R, Alloway RR, Gaber AO, Schroeder TJ, Irish WD, Canafax DM, First MR 1999. Pharmacokinetics and safety evaluation of SangCya vs Neoral or Sandimmune in stable retransplant recipients Transplant Proc, 31 , 326-327Meier-Kriesch HU, Alloway RR, Gaber AO, Canafax D, Kaplan B 1999. A limited sampling strategy (LSS) for the estimation of 12-hour SangCya and Neoral AUCs in renal transplant recipients J Clin Pharmacol, 39 , 166-167Reddy KS, Stratta RJ, Shokouh-Amiri MH, Alloway RR, Egidi MF, Gaber AO 1999. Surgical complications after pancreas transplantation with portal-enteric drainage J Am Coll Surg, 189 , 305-313Stratta RJ, Gaber AO, Shokouh-Amiri MH, Reddy KS, Alloway RR, Egidi MF, Grewal HP, Gaber LW, Hathaway D 1999. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction Ann Surg, 229 , 709-712Stratta RJ< Gaber AO, Shoukouh-Amiri MH, Reddy S, Alloway RR, Egidi MF, Grewal HP, Gaber LW, Hathaway DK 1999. Evolution in Pancreas Transplantation Techniques: Simultaneous Kidney-Pancreas Transplantation Using Portal-Enteric Drainage Without Antilymphocyte Induction Ann Surg, 229 , 701-712Alloway RR, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO 1998. Bioequivalence comparison of Snadimmune and Neoral versus Sang-35 cyclosporine in kidney transplant recipients J Am Soc Nephrol, 8 , 672AFirst MR, Alloway RR, Schroeder TJ 1998. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral Clin Transplantation, 12 , 518-524Hurst G, Alloway RR, Hathaway D, Somerville T, Hughes T, Gaber AO 1998. Stabilization of bone mass after renal transplant with preemptive care Transplant Proc, 30 , 1327-1328Somerville T, Hurst G, Alloway RR, Gaber AO, Shokouh-Amiri MH, Stratta R 1998. Superior efficacy of oral gancyclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients Transplant Proc, 30 , 1546-1548Stratta RJ, Alloway RR 1998. Pancreas transplantation for diabetes mellitus: A guide to recipient selection and optimum immunosuppression Biodrugs, 10 5, 347-357Winsett RP and the Posttransplant Quality of Life Intervention Study Group 1998. Posttransplant quality of life: a decade of descriptive studies leading to practice interventions J Transplant Coordination, 8 , 236-240Gaber LW, Moore LW, Reed L, Russell W, Alloway R, Hathaway D, Shokough-Amiri MH, Gaber AO 1997. Renal histology with varying FK 506 blood levels Transplant Proc, 29 , 186Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO 1996. Conversion from Cyclosporine to tacrolimus in kidney, kidney/pancreas and pancreas alone transplant recipients: the Memphis Experience Transplant Proc, 28 , 995-997Elmer D, Nymann T, Hathaway D, Alloway RR, Gaber AO 1996. Use of FK-506 immunosuppression in pancreas transplant J Transplant Coordination, 6 , 122-127Gaberr LW, Moorle LW, Alloway RR, Flax S, Schroeder T, Amiri H, Gaber AO 1996. Correlation between BANFF scores of acute renal rejection scores and reversal of rejection Kidney Int, 49 , 481-497Moore LW, Alloway RR, Smith SO, Acchiardio SR, Gaber AO 1996. Clinical obsevations of metabolic changes occurring in renal transplant recipients receiving ketoconazole Transplantation, 61 , 537-541Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO 1996. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation Clin Transplantation, 10 , 633-667Self T, Alloway R 1996. Treatment of Rhinitis J Am Acad Nurse Pract, 8 , 135-144Gaber LW, Moore LW, Alloway RR, Flax S, Gaber AO 1995. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection Transplant Proc, 27 , 1019Gaber LW, Moore LW, Alloway RR, Shokouh-Amiri MH, Vera SR, Gaber AO 1995. Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts Transplantation, 60 , 334-339Alloway RR, Kotb M, Hathaway D, Ohman M, Gaber AO 1994. Pharmacokinetic Profile of OKT3 in Renal Transplant Recipients Receiving Standard and Low Dose OKT3 for Induction Immunosuppression Transplantation, 58 , 249-253Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1993. Results of Prospective, Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy Transplant Proc, 25 1, 550-552Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1993. Results of a Prospective, Randomized, Double-Blind Study Comparing Standard versus Low Dose OKT3 Induction Therapy American Journal of Kidney Diseases, 22 36-43, Self T, Heilker G, Alloway RR, Kelso T, Abou-Shala N 1993. Reassessing the Therapeutic Range for Theophyilline on Laboratory Report Forms: The Importance of 5-15 mcg/ml Pharmacotherapy, 13 6, 590-594Alloway RR, Kotb M, Gaber L, Boskey F, Gaber AO 1992. Standard versus Low Dose OKT3 Induction of Cadaveric Renal Transplants: Compairson of Outcome Data versus OKT3 Dose and Serum LEvels Clin Transplantation, 46 , 468-472Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 1992. Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients Scientia, 1 6, Kelso TM, Alloway RR, Self TH 1992. Asthma Patient Education Journal of Pharmacy Practice, 5 , 186-196Busque S, Cantarovich M, Mulgonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators 12-2011. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation Am J Transplant, 11 12, 2675-2684Trofe-Clark J, Gabardi S, McDevitt-Potter L, Alloway RR 12-17-2011. Immunosuppression. Generic Drugs and the FDA Am J Transplant, , Bruce DS, Sollinger HW, Humar A, Sutherland DER, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ 11-27-2001. Multicenter Survey of Daclizumab Induction in Simultaneous Kidney-Pancreas Transplant Recipients Transplantation, 72 10, 1637-1643Buell JF, Alloway RR, Woodle ES 10-2006. How can donors with a previous malignancy be evaluated? J Hepatol, 45 4, 503-507Rogers J, Stratta RJ, Lo A, Alloway RR 10-2005. Impact of metabolic syndrome on long-term outcomes in simultaneous kidney-pancreas transplantation Transplant Proc, 37 8, 3549-3551Stratta RJ, Alloway RR, Lo A, Hodge E 10-2005. Risk factors and outcomes analyses of a prospective, randomized, multicenter trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients Transplant Proc, 37 8, 3527-3530Winsett RP, Arheart K, Stratta RJ, Alloway RR, Wicks MN, Gaber AO, Hathaway DK 09-2004. Evaluation of an immunosuppressant side effect instrument Prog Transplant, 14 3, 210-216Honaker MR, Amiri S, Vera SR, Alloway RR, Grewal HP, Hardinger KL, Kizilisik TA, Bagous T, Trofe J, Stratta RJ, Egidi MF, Gaber AO 09-2002. Evolving experience of HBV prophylaxis in liver transplantation Transplant Infectious Disease , 4 3, 137-143Self T, Alloway R 09-1993. Nonsedating Antihistamines Pharmacy Newsletter, , Alloway RR, Dupuis R, Gabardi S, Kaiser TE, Taber DJ, Tichy EM, Weimert-Pilch NA; American Society of Transplantation Transplant Pharmacy Community of Practice and the American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network 08-2011. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team Am J Transplant, 11 8, 1576-1583Woodle ES, Alloway RR, Girnita A 08-2011. Proteasome inhibitor treatment of antibody-mediated allograft rejection Curr Opin Organ Transplant, 16 4, 434-438Buell JF, Thomas GG, Thomas MJ, Neff G, Muthiah C, Alloway RR, Woodle ES 08-2006. Malignancy in pediatric transplant recipients Seminars in Pediatric Surgery, 15 3, 179-187Gaber AO, Mulgaonkar S, Kahan BD, Woodle ES, Alloway RR, Bajjoka I, Jensik S, Klintmalm GB, Patton PR, Wiseman A, Lipshutz G, Kupiec-Weglinski J, Gaber LW, Katz E, Irish W, Squiers EC, Hemmerich S 07-2011. YSPSL (rPSGL-Ig) for improvement of early renal allograft function; a double-blind, placebo-controlled, multi-center Phase IIa study Clin Transplant, 25 4, 523-533Rogers CC, Alloway RR, Buell JF, Boardman R, Aelxander JW, Cardi M, Roy-Chaudhury P, First MR, Succop P, Munda R, Woodle ES 07-15-2005. Body weight alterations under early coticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression Transplantation, 80 1, 26-33Alloway RR, Steinburg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsh J, Martas A, Zaltzman J, Wisemandel K, Fitzsimmons W, First MR 06-27-2007. Two years postconversion from a prograf-based regimen to a once daily tacrolimus extended-release formulation in stable kidney transplant recipients Transplantation, 83 12, 1648-1651Florman S, Alloway RR, Kalayoglu M, Punch J, Bak T, Melancon J, Klintmalm G, Busque S, Charlton M, Lake J, Dhadda S, Wisemandle K, Wirth M, Fitzsimmons W, Holman J, First MR 06-27-2007. Once daily tacrolimus extended release formulation: experience at 2 years post conversion from a Prograf-based in stable liver transplant recipients Transplantation, 83 12, 1639-1642Reddy KS, Stratta RJ, Alloway RR, Lo A, Hodge EE; PIVOT Study Group 05-2004. The impact of delayed graft function of the kidney on the pancreas allograft in simultaneous kidney-pancreas transplantation Transplant Proc, 36 4, 1078-1079Stratta RJ, Alloway RR, Hodge E, Lo A, PIVOT Investigators 05-2004. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients Transplant Proc, 36 4, 1082-1083First MR, Alloway RR, Fisher RA, Pan SH, Lopez R, Renlund D, Schnitzler M, Gaber AO 05-2000. Generic drug substitution in transplantation: examples from the epic of Cyclosporine development Dialysis and Transplantation, 29 5, 260-267Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES 04-2004. Polyomavirus in Solid Organ Transplantation Progress in Transplantation, 14 2, 130-140Vasilic D, rteynolds CC, Cunningham M, Furr A, Storey B, Banis JC, Wiggins O, Maldonado C, Alloway RR, Kon M, Barker JH 03-2008. Plastic surgeon's risk acceptance in facial transplantation Plast Recontstr Surg, 121 3, 41e-48eFlorman S, Alloway RR, Kalayoglu M, Lake K, Bak T, Klein A, Klintmalm G, Busque S, Brandenhagen D, Lake J, Widemandle K, Fitzsimmons W, First MR 03-2005. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen Transplant Proc, 37 2, 1211-1213Lo A, Stratta RJ, Alloway RR, Hodge EE; PIVOT Study Group 03-2005. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation Transplant Proc, 37 2, 1289-1290Walker JK, Alloway RR, Roy-Chaudhury P, Mogilishetty G, Cardi M, Weimert NA, Rike AH, First MR, Woodle ES 02-15-2006. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in HLA identical live donor renal transplantation Transplantation, 87 3, 408-414Aull MJ, Buell JF, Peddi VR, Trode J, Beebe TM, Hanaway MH, Roy-Chaudhury P, Alloway RR, First MR, Woodle ES; Israel Penn International Transplant Tumor Registry 01-2002. MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report form the Israel Penn International Transplant Tumor Registry with a review of published literature Transplantation, 75 2, 225-228Alloway RR 01-1994. Spotlight of Heparin Dosing. Drug Information Update, Allied Pharmacy Management Inc, ,
Abstract Publications Merchen T, Gupta M, First MR, Trofe J, Gross TG, Bebe TM, Alloway RR, Muthiah C, Hanaway MG, Buells JF, Woodle ES 2003. PTLD following lung transplantation American Transplant Congress, Washington, D.C., , Aull MJ, Trofe J, First MR, Hanaway M, Beebe TM, Alloway RR, Woodle ES, Buell JF 2001. Maltoma: infectious etiology of malignancy in transplant patients International Transplant Nurses Society, , Beebe TM, Buell JF, Alloway RR, Hanaway MJ, First MR, Woodle ES 2001. Donor transmission of a renal cell carcinoma from a living related donor to a kidney recipient International Transplant Nurses Society, , Moore LW, Alloway RR, Smith SO, Acchiardio SR, Gaber AO 1995. Ketaconazole enhances loss of bone in renal transplant recipients American Society of Transplantation Physicians Annual Meeting, , Alloway RR, Kotb M, Hathaway D, Schroeder T, Gaber AO 1994. Demographic and clinical factors effecting TCR expression during and following OKT3 treatment The American Society of Nephrology, , Gaber L, Moore L, Alloway RR, Flax S, Gaber AO 1994. Correlation Between BANFF Classification, Acute Renal Rejection Scores and Reversal of Rejection American Society of Transplantation Physicians, , Gaber L, Vera S, Hathaway D, Salem A, Alloway RR, Gaber AO 1993. Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function American Society of Nephrologists/National Kidney Foundation, , Gaber L, Vera S, Hathaway D, Salem A, Alloway RR, Gaber AO 1992. Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function National Kidney Foundation, , Gaber AO, Kotb M, Winsett RP, Gaber LW, Vera SR, Phillips D, Boskey FD, Alloway RR 1991. Standard Versus Low Dose OKT3 Induction: Comparison of Immune Monitoring Data and Results. Proceedings of the American Society of Transplant Physicians, , 1Winsett RP, Hathaway DK, Alloway RR, Gaber AO 1991. Effective and Safe Use of Ketoconazole as Adjunctive Immunosuppressive Therapy. North American Transplant Coordinators Organization, , Gaber AO, Shoukouh-Amiri MH, Stratta RJ, Reddy KS, Alloway RR, Britt LG 12-1998. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction Southern Surgical Association Annual Meeting, , Sollinger HW, Bruce DS, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, Alloway RR, Stratta RJ 08-1999. Multicenter analysis of Daclizumab induction in simultaneous kidney pancreas transplant recipients 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS 08-1999. A single center experience with 108 cases of pancreas transplantation with portal-enteric drainage 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS, Gaber AO 08-1999. Graft failure after solitary pancreas transplantation 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS, Gaber AO 08-1999. Patterns of graft loss after simultaneous kidney-pancreas transplantation according to technique and immunosuppressive era 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO 08-1995. Conversion from cyclosporine to FK-506 in kidney, kidney/pancreas and pancreas alone transplant recipients. A single center experience Minneapolis Transplant Congress: New Immunosuppressive Drugs, Minneapolis, MN, , Elmer D, Nymann T, Hathaway D, Alloway RR, Gaber AO 08-1995. Use of FK0506-based immunosuppression in pancreas transplantation National Association of Transplant Coordinators Organization Annual Meeting, Boston, MA, , Regan J, Alloway RR, Rossi S, Campbell K, Buelow R, Lankford M, Gaber AO 07-1998. Clinical monitoring of cyclosporine: Capillary whole blood collected with the cyclostat collection device XVII World Congress of the International Transplant Society, Montreal, Canada, , Gaber LW, Lo A, Egidi MF, Stratta RJ, Amiri MH, Grewal HP, Kizilisik T, Alloway RR, Gaber AO 05-2000. Relationship of histological and clinical features of first acute rejection on recurrent rejection and pancreas failure First Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, , Stratta RJ, Allwoay RR, Hodge E 05-2000. An open-label, comparative trial of two Daclizumab dosing strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients: Interim analysis First Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, , Egidi MF, Trofe J, Reed L, Gaber LW, Alloway RR, Shoukouh-Amiri MH, Stratta RJ, Gaber AO 05-1999. Risk factors for polyoma virus: A comparative analysis in kidney-pancreas and kidney transplants 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Sollinger HW, Bruce D, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, Alloway RR, Stratta RJ 05-1999. Multicenter retrospective analysis of simultaneous kidney pancreas transplant recipients receiving Daclizumab induction 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Trofe J, Alloway RR, Godkin J, Kano J, Stratta RJ, Gaber AO 05-1999. Thymoglobulin for the prophylaxis or treatment of rejection in pancreas allograft recipients: Results of the US compassionate use experience 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Alloway RR, Canafax D, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO 05-1998. Bioequivalence of Snag-25 and Neoral for cyclosporine metabolites in stable renal transplant patients American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Hurst GC, Alloway RR, Somerville KT, Gaber AO, Stratta RJ 05-1998. Preliminary experience with midodrine in kidney/pancreas transplant patients experiencing orthostatic hypotension American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Hurst GC, Somerville KT, Alloway RR, Hathaway D, Moore LW, Gaber AO 05-1998. Continued loss of bone density one-year post kidney transplant despite preemptive therapy American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Alloway RR, Johnson JA, Chaballa M, Russell W, Reed L, Hathaway DK, Amiri H, Vera SR, Gaber AO 05-1997. Effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients American Society of Transplantation Surgeons Annual Meeting, Chicago, IL, , Alloway RR, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO 05-1997. An open-labeled single center bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Chaballa M, Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 05-1997. Five-year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Schroeder TJ, First R, Alloway RR, Gaber AO, Levy R, Berger-Moran H, Floch R, Pouletty P 05-1997. A program to develop cyclosporine formulation that is bioequivalent to Neoral American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Gaber LW, Moore LW, Russell W, Alloway RR, Gaber AO 05-1996. Donor glomerulosclerosis impacts both short- and long-term renal allograft function American Society of Transplantation Physicians Annual Meeting, Dallas, TX, , Gaber LW, Moore L, Alloway RR, Flax S, Schroeder T, Amiri H, Gaber AO 05-1995. Correlation between BANFF scores of acute renal rejection scores and reversal of rejection American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Gaber LW, Moore LW, Alloway RR, Shokouh-Amirir MH, Vera SR, Gaber AO 05-1995. Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Rageuh I, Kotb M, Fraga D, Schroeder T, Chan F, Russell WC, Alloway RR, Gaber AO 05-1995. A comparison of methodologies used for measurement of circulating OKT3 levels American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Abell TL, Horn J, Adl D, Self T, Soberman J, Alloway RR, Thompson L 04-1999. Correlation of cisapride levels with EKG changes: A pilot clinical observation Digestive Diseases Week Meeting of the American Gastroenterology Association, , Mendez R, Noriega A, Lowance D, Alloway RR, Lee I, Coggon G 03-1997. Valaciclovir reduces the incidence of CMV disease CMV-seropositive cadaveric renal allograft recipients Sixth Internatioanl Cytomegalovirus Workshop, Minneapolis, MN, , Nymann T, Vera SR, Amiri MH, Riely C, Alloway RR, Gaber AO 01-1996. Prevention of Hepatitis B recurrence with indefinite immunoprophylaxis after liver transplantation South Eastern Organ Procurement Foundation Tri-Annual Meeting, Orlando, FL, ,
Merchen T, Gupta M, First MR, Trofe J, Gross TG, Bebe TM, Alloway RR, Muthiah C, Hanaway MG, Buells JF, Woodle ES 2003. PTLD following lung transplantation American Transplant Congress, Washington, D.C., , Aull MJ, Trofe J, First MR, Hanaway M, Beebe TM, Alloway RR, Woodle ES, Buell JF 2001. Maltoma: infectious etiology of malignancy in transplant patients International Transplant Nurses Society, , Beebe TM, Buell JF, Alloway RR, Hanaway MJ, First MR, Woodle ES 2001. Donor transmission of a renal cell carcinoma from a living related donor to a kidney recipient International Transplant Nurses Society, , Moore LW, Alloway RR, Smith SO, Acchiardio SR, Gaber AO 1995. Ketaconazole enhances loss of bone in renal transplant recipients American Society of Transplantation Physicians Annual Meeting, , Alloway RR, Kotb M, Hathaway D, Schroeder T, Gaber AO 1994. Demographic and clinical factors effecting TCR expression during and following OKT3 treatment The American Society of Nephrology, , Gaber L, Moore L, Alloway RR, Flax S, Gaber AO 1994. Correlation Between BANFF Classification, Acute Renal Rejection Scores and Reversal of Rejection American Society of Transplantation Physicians, , Gaber L, Vera S, Hathaway D, Salem A, Alloway RR, Gaber AO 1993. Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function American Society of Nephrologists/National Kidney Foundation, , Gaber L, Vera S, Hathaway D, Salem A, Alloway RR, Gaber AO 1992. Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function National Kidney Foundation, , Gaber AO, Kotb M, Winsett RP, Gaber LW, Vera SR, Phillips D, Boskey FD, Alloway RR 1991. Standard Versus Low Dose OKT3 Induction: Comparison of Immune Monitoring Data and Results. Proceedings of the American Society of Transplant Physicians, , 1Winsett RP, Hathaway DK, Alloway RR, Gaber AO 1991. Effective and Safe Use of Ketoconazole as Adjunctive Immunosuppressive Therapy. North American Transplant Coordinators Organization, , Gaber AO, Shoukouh-Amiri MH, Stratta RJ, Reddy KS, Alloway RR, Britt LG 12-1998. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction Southern Surgical Association Annual Meeting, , Sollinger HW, Bruce DS, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, Alloway RR, Stratta RJ 08-1999. Multicenter analysis of Daclizumab induction in simultaneous kidney pancreas transplant recipients 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS 08-1999. A single center experience with 108 cases of pancreas transplantation with portal-enteric drainage 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS, Gaber AO 08-1999. Graft failure after solitary pancreas transplantation 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS, Gaber AO 08-1999. Patterns of graft loss after simultaneous kidney-pancreas transplantation according to technique and immunosuppressive era 7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia, , Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO 08-1995. Conversion from cyclosporine to FK-506 in kidney, kidney/pancreas and pancreas alone transplant recipients. A single center experience Minneapolis Transplant Congress: New Immunosuppressive Drugs, Minneapolis, MN, , Elmer D, Nymann T, Hathaway D, Alloway RR, Gaber AO 08-1995. Use of FK0506-based immunosuppression in pancreas transplantation National Association of Transplant Coordinators Organization Annual Meeting, Boston, MA, , Regan J, Alloway RR, Rossi S, Campbell K, Buelow R, Lankford M, Gaber AO 07-1998. Clinical monitoring of cyclosporine: Capillary whole blood collected with the cyclostat collection device XVII World Congress of the International Transplant Society, Montreal, Canada, , Gaber LW, Lo A, Egidi MF, Stratta RJ, Amiri MH, Grewal HP, Kizilisik T, Alloway RR, Gaber AO 05-2000. Relationship of histological and clinical features of first acute rejection on recurrent rejection and pancreas failure First Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, , Stratta RJ, Allwoay RR, Hodge E 05-2000. An open-label, comparative trial of two Daclizumab dosing strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients: Interim analysis First Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL, , Egidi MF, Trofe J, Reed L, Gaber LW, Alloway RR, Shoukouh-Amiri MH, Stratta RJ, Gaber AO 05-1999. Risk factors for polyoma virus: A comparative analysis in kidney-pancreas and kidney transplants 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Sollinger HW, Bruce D, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, Alloway RR, Stratta RJ 05-1999. Multicenter retrospective analysis of simultaneous kidney pancreas transplant recipients receiving Daclizumab induction 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Trofe J, Alloway RR, Godkin J, Kano J, Stratta RJ, Gaber AO 05-1999. Thymoglobulin for the prophylaxis or treatment of rejection in pancreas allograft recipients: Results of the US compassionate use experience 18th Annual Meeting of the American Society of Transplantation, Chicago, IL, , Alloway RR, Canafax D, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO 05-1998. Bioequivalence of Snag-25 and Neoral for cyclosporine metabolites in stable renal transplant patients American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Hurst GC, Alloway RR, Somerville KT, Gaber AO, Stratta RJ 05-1998. Preliminary experience with midodrine in kidney/pancreas transplant patients experiencing orthostatic hypotension American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Hurst GC, Somerville KT, Alloway RR, Hathaway D, Moore LW, Gaber AO 05-1998. Continued loss of bone density one-year post kidney transplant despite preemptive therapy American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Alloway RR, Johnson JA, Chaballa M, Russell W, Reed L, Hathaway DK, Amiri H, Vera SR, Gaber AO 05-1997. Effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients American Society of Transplantation Surgeons Annual Meeting, Chicago, IL, , Alloway RR, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO 05-1997. An open-labeled single center bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Chaballa M, Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO 05-1997. Five-year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Schroeder TJ, First R, Alloway RR, Gaber AO, Levy R, Berger-Moran H, Floch R, Pouletty P 05-1997. A program to develop cyclosporine formulation that is bioequivalent to Neoral American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Gaber LW, Moore LW, Russell W, Alloway RR, Gaber AO 05-1996. Donor glomerulosclerosis impacts both short- and long-term renal allograft function American Society of Transplantation Physicians Annual Meeting, Dallas, TX, , Gaber LW, Moore L, Alloway RR, Flax S, Schroeder T, Amiri H, Gaber AO 05-1995. Correlation between BANFF scores of acute renal rejection scores and reversal of rejection American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Gaber LW, Moore LW, Alloway RR, Shokouh-Amirir MH, Vera SR, Gaber AO 05-1995. Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Rageuh I, Kotb M, Fraga D, Schroeder T, Chan F, Russell WC, Alloway RR, Gaber AO 05-1995. A comparison of methodologies used for measurement of circulating OKT3 levels American Society of Transplantation Physicians Annual Meeting, Chicago, IL, , Abell TL, Horn J, Adl D, Self T, Soberman J, Alloway RR, Thompson L 04-1999. Correlation of cisapride levels with EKG changes: A pilot clinical observation Digestive Diseases Week Meeting of the American Gastroenterology Association, , Mendez R, Noriega A, Lowance D, Alloway RR, Lee I, Coggon G 03-1997. Valaciclovir reduces the incidence of CMV disease CMV-seropositive cadaveric renal allograft recipients Sixth Internatioanl Cytomegalovirus Workshop, Minneapolis, MN, , Nymann T, Vera SR, Amiri MH, Riely C, Alloway RR, Gaber AO 01-1996. Prevention of Hepatitis B recurrence with indefinite immunoprophylaxis after liver transplantation South Eastern Organ Procurement Foundation Tri-Annual Meeting, Orlando, FL, ,